

16th Annual Report





BERYL DRUGS LIMITED SIXTEENTH ANNUAL REPORT 2008-2009 CORPORATE INFORMATION

BOARD OF DIRECTORS :

Shri Sanjay Sethi - Managing Director Shri Sudhir Sethi - Whole-time Director Shri Sunil Jain - Chairman cum Director Shri Hemant Jain - Director

BOARD COMMITTEES :

Audit & Remuneration Committee :

Shri Sunil Jain - Chairman

Shri Hemant Jain - Member

Shri Sudhir Sethi - Member

SHARE TRANSFER /SHAREHOLDER GRIEVANCE COMMITTEE :

Shri Hemant Jain - Chairman. Shri Sudhir Sethi - Member Shri Sunil Jain - Member

AUDITORS :

SUBHASH CHAND JAIN ANURAG & ASSOCIATES Chartered Accountants. 4, Archana Apartment, 8-B, Ratlam Kothi, Indore - 452 001.

REGISTERED OFFICE :

133, Kanchan Bag, Indore - 452 001.

BANKERS :

Punjab National Bank, Indore

LISTED STOCK EXCHANGES :

- 1. M.P. STOCK EXCHANGE 201, Palika Plaza, MTH Compound, Indore
- THE STOCK EXCHANGE, MUMBAI Phiroze Jeejeebhoy Tower Dalal Street, Fort, MUMBAI - 400 001
- 3. THE STOCK EXCHANGE, AHMEDABAD Kamdhenu Complex, Opp. Shahajanand College, Panjarpole, Ahmedabad - 380015

REGISTRAR AND SHARE TRANSFER AGENT :

M/s. Adroit Corporate \$ Service (P) Ltd.

19/20, Jaferbhoy, Industrial Estate, 1st Floor Makawana Road,

Marol Naka, Andheri (E),Mumbai, 400 059 E-mail: adroit@vsnl.net Ph. 022 - 28596060, 28594060 Fax - 28503748

ANNUAL GENERAL MEETING

Date & : September 30, 2009 Time at 10.00 a.m.

Day : Wednesday

Venue : Kanchan Palace, Community Hall, Nipania, Ring Road, Indore (M.P.)

CONTENTS	No.
Corporate Information	01
Notice of AGM	03
Directors' Report	05
Corporate Governance Report	09
Shareholders Information	11
Auditors' Certificate on Corporate	é.
Governanace	13
Auditors' Report	16
Balance Sheet	20
Profit and Loss Account	21
Schedules and Notes	22

NOTICE

NNotice is hereby given that the Sixteenth Annual General Meeting of the Company will be held on Wednesday, the 30th day of September, 2009 at 10.00 A.M. at the Kanchan Palace, Community Hall, Nipania, Ring Road, ndore - 452 001 (M.P.) to transact the following business:

ORDINARY BUSINESS:

16TH ANNUAL REPORT

- 1. To receive, consider and adopt the audited Balance Sheet as at 31st March 2009 and Profit & Loss Account for the year ended on that date along with Reports of Directors and Auditors thereon.
- 2. To appoint a Director in place of Mr. Sunil Jain, who retires by rotation and, being eligible, offers himself for reappointment.
- 3. To appoint M/s Subhash Chand Jain Anurag & Associates, Chartered Accountants, Indore, as Auditors of the Company to hold office from the conclusion of this meeting until the conclusion of the next Annual General Meeting and fix their remuneration.

SPECIAL BUSINESS :

4. To consider and if thought fit, to pass, with or without modification, the following resolutions as an Ordinary Resolution

RESOLVED THAT Subject to approval of shareholder and pursuant to section 264 of the Companies Act, 1956 Mr. Avinash Sharma whose candidature is proposed by members and who has filed his consent to act as a director of the Company be and is hereby appointed as a Director of the Company whose period of office shall be liable to determination by retirement of Directors by rotation.

RESOLVED FUTHER THAT Shri Sudhir Sethi, Director of the Company be and is hereby authorized to do all such acts and deeds and file all such forms, documents, papers etc. as may be necessary in this regard."

Notes :

 A member entitled to attend and vote at the meeting is entitled to appoint a proxy and to attend and on a poll to vote instead of himself and the proxy need not be a member of the Company. A member unable to attend may appoint a person (whether a member or not) as his proxy in the enclosed form which shall be deposited with the principal office of the Company.

THE PROXIES IN ORDER TO BE EFFECTIVE MUST BE RECEIVED BY THE COMPANY NOT LESS THAN 48 HOURS BEFORE THE MEETING.

- 2. The register of members and share transfer books of the Company will remain closed form September 22, 2009 to September 30, 2009 (both days inclusive).
- 3. Members are requested to intimate immediately any change in their addresses at the registered office of the Company.
- 4. Shareholders desiring any information on the Accounts at the Annual General Meeting are requested to intimate the Company at least 7 days in advance so, as to enable the Company to keep the information ready.
- 5. Shareholders are requested to bring their copy of Annual Report to the meeting along with the attendance slip.
- 6. The members holding shares in identical order of names in more than one folio are requested to write to the Share transfer agent of the Company to consolidate their holding in one folio.
- 7. Members are requested to quote their Folio Number in all their correspondence.
- 8. The documents referred to in this notice/ Explanatory Statements are open for inspection by the members at the principal office of the Company during the business hours of the Company on any working day upto the last date of the Annual General meeting.

Place : Indore Dated : 13th August, 2009 By order of the Board For Beryl Drugs Limited SD/-(SANJAY SETHI) MANAGING DIRECTOR

\equiv	16TH ANNUAL REPORT		<u> </u>

ADDITIONAL INFORMATION

Brief resume and other information in respect of Directors seeking appointment at the Annual General Meeting:

1. Mr. Avinash Sharma :

Mr. Avinash Sharma, aged about 44 years, is a Graduate in Arts. He has rich experience of about 30 years in the field of Drugs marketing, accounts, finance etc.

He does not hold any shares in the company.

Nature of expertise in specific functional areas - Drugs marketing, accounts, finance etc.

EXPLANATORY STATEMENT PURSUANT TO SECTION 173(2) OF THE COMPANIES ACT, 1956

For Item No. 4:

The Company has received a notice in writing from a member along with required deposit, proposing the candidature of Mr. Avinash Sharma for the office of Director under the provisions of Section 257 of the Companies Act, 1956. A brief profile of Mr. Avinash Sharma is given hereto under the head "additional information".

Your Directors recommend the resolution as set out at item no. 4 of the notice for your approval.

Mr. Avinash Sharma shall be deemed to be interested in the above resolution to the extent of his appointment.

Place : Indore Dated : 13th August, 2009 By order of the Board For Beryl Drugs Limited SD/-(SANJAY SETHI) MANAGING DIRECTOR

DIRECTORS' REPORT

Τo,

The Members, Beryl Drugs Limited INDORE

Your Directors have pleasure in presenting their Sixteenth Annual Report of the Company together with the Audited Accounts for the financial year ended on 31st March 2009.

(Runnes in Lace)

1. FINANCIAL RESULTS AND OPERATION:

The Company's financial results have been summarised as follows:

		(Rupees in Lacs)
	Year ended	Year ended
	31.3.2009	31.3.2008
Total Income	70528.58	65675.08
Total Expenditure	70241.93	64941.42
Profit before prior period adjustment	286.64	733.66
Less: Prior period adjustment	5.78	281.16
Profit before Tax	280.87	452.50
Less: Provision for Income Tax	128.87	437.45
Profit after Tax	152.00	15.04
Profit/ (Loss) brought forward from last year	4121.52	3889.42
Balance of Profit/(loss) carried to Balance Sheet	4273.52	4121.52

Due to the adverse domestic and international market conditions, the turnover of the Company of this year is Rs. 69841029.82 against the turnover of Rs. 62258420.07 recorded during the previous year, and thus resulted in decreased in the profit before tax of the Company to Rs. 280868.97 as against Rs. 452498.33 in the previous year. Your Directors expect a better performance in the coming years.

Your management is very hopeful to achieve better results in forthcoming period and expects to achieve better financial results as per the perception of the Shareholders of the Company.

The Company has tried to put every effort so that the customer's satisfaction spirit of the company remains unquestionable and the company achieves new heights of success.

2. DIVIDEND :

In order to further strengthen the Company to expand its business activities and to conserve the financial resources, your Directors regret for their inability to recommend any dividend for the financial year 2008-09.

3. PUBLIC DEPOSITS :

The Company has neither invited nor accepted any deposit from the public with in the Section 58A of the Companies Act, 1956 read with the Companies (Acceptance of Deposit) Rules, 1975 during the year.

4. MANAGEMENT :

Shri Sunil Jain, Director of the Company, retire by rotation at the date of ensuing Annual General Meeting and being eligible offers himself for the re-appointment. A motion for the re-appointment of Shri Sunil Jain, as Director of the Company will be placed before the Members in the ensuing AGM.

5. DIRECTOR'S RESPONSIBILITY STATEMENT :

Pursuant to the provision of Section 217 (2AA) of the Companies Act, 1956 as amended with respect to Director's responsibility statement and subject to where so ever otherwise contained in the Audit Report, Your

Directors hereby confirm.

- 1. That in the preparation of the annual accounts for the financial period ended on 31st March, 2009 the applicable accounting standards subject to notes to the accounts in Auditors Report had been followed, along with proper explanation relating to material departures;
- That the Director have selected such accounting policies and applied them consistently and made judgements and estimates that are reasonable and prudent, so as to give a true and fair view of the state of affairs of the Company at the end of the financial period ended and profit of the Company for the period under review;
- 3. That the Directors have taken proper and sufficient care for the maintenance of adequate accounting records, in accordance with the provisions of the Companies Act, 1956 for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- 4. That the Directors have prepared the annual accounts on a going concern basis.

6. AUDITORS :

The statutory auditors of the Company, M/s. Subhash Chand Jain Anurag & Associates, Chartered Accountants, Indore (M.P.) retires at the conclusion of the forthcoming Annual General Meeting and being eligible offer themselves for reappointment.

The Company has received a certificate from M/s. Subhash Chand Jain Anurag & Associates to the effect that their appointment, if made, would be within the limits under Section 224(1B) of the Companies Act, 1956.

Yours Directors recommend their appointment as auditors of the Company in ensuing Annual General Meeting.

7. AUDITOR'S REPORT:

The Auditors Report on the accounts for this accounting period ended on 31st March 2009 is self-explanatory, therefore does not require any further explanation.

8. INSURANCE

The Company's plant, property, equipment, machinery and stocks are adequately insured against various mis-happenings.

9. PARTICULARS OF EMPLOYEES

The information as required under Section 217(2A) of the Companies Act, 1956 read with the Companies (Particulars of Employees) Rules, 1975 are not applicable to the Company as the Company does not have any employee receiving Remuneration exceeding Rs. 24,00,000.00 per annum or Rs. 2,00,000.00 per month or part thereof.

10. DISCLOSURE OF CONSERVATION OF ENERGY, TECHNOLOGY, ABSORPTION AND FOREIGN EXCHANGE EARNING AND OUTGO.

The details of energy conservation, technology absorption etc., in Form A and B as required under section 217(1)(e) are annexed to and forming part of the report of the Board. There is no foreign exchange earning and outgo during the year.

11. CORPORATE GOVERNANCE:

The Company has complied with the mandatory statutory requirement of corporate Governance specified by the Securities and Exchange Board of India through Clause 49 of the Listing agreement. As required by the said clause, a separate report on the Corporate Governance forms part of this Annual report.

A certificate form the Statutory Auditors of the Company regarding compliance of conditions of Corporate Governance has been obtained and is enclosed to this report

12. LISTING OF SECURITIES :

The Equity Shares of the Company are listed with the Stock Exchanges of Mumbai, and Madhya Pradesh. Delisting of the Company's securities from the Ahemdabad Stock Exchanges is under Processing.

16TH ANNUAL REPORT		BERYL		

13. INTERNAL CONTROL SYSTEM:

The company has reasonable internal control system comprising authority levels and powers, supervision, checks and balances, policies, procedures and internal audit. The system is reviewed and updated on an on going basis. The Company is continuously upgrading its internal control systems by measures such as strengthening of Information Technology infrastructure and use of external management assuring services. However there is inherent limitation, including the cost of control that should be recognized in weighing the assurances providing by any systems of internal control

14. APPRECIATION AND ACKNOWLEDGEMENT

Your Directors appreciated the trust reposed by the medical fraternity and patients in the Company and look forward to their continued patronage. Your Directors are also grateful and pleased to place on record their appreciation and acknowledgement with gratitude the support and Company-operation extended by clients, customers, vendors, bankers, investors, media and both the State and central Government and their agencies and look forward their continued support.

By order of the Board For Beryl Drugs Limited SD/-(SANJAY SETHI) MANAGING DIRECTOR

Place : Indore Dated : 18th August, 2009

ANNEXURE TO DIRECTORS' REPORT

Particulars required under the Companies (Disclosure of particulars

In the Report of Board of Directors) Rules 1988.

FORM - A

(Form for disclosure of particulars with respect to the conservation of energy)

(i) CONSERVATION OF ENERGY

The Company continues to take measure for conservation of energy required to produce products including regular checks and preventive maintenance of all electrical equipment and installation are being conducted to avoid leakage of energy due to faulty operations.

	2008-2009	<u>2007-2008</u>
Electricity	1	
a. Purchased Quantity (Unit)	353790	408363
Total Amount (Rs. in lacs)	21.77	21.62
Average Rate per unit (Rs)	6.15	5.29
Coal		
a. Quantity in M.T.	652.490	693.942
b. Total Amount (Rs. In Lacs)	24.67	21.96
c. Average Rate per M.T. (in Rs.)	3781.67	3165.76
Diesel		
a. Quantity in M.T.	1015	NIL
b. Total Amount (Rs. In Thousand)	0.40	NIL
c. Average Rate per M.T. (in Rs.)	39.40	NIL

(ii) CONSUMPTION PER UNIT OF PRODUCTION

The Company manufactures several injections. It is therefore difficult to apportion the consumption and cost of utilities to specific products item.

FORM B

(Forms for disclosure of particulars with respect to Technology Absorption)

- 1. Research and Development work concerning process improvements of small volume injections and large volume injections are carried out at Company's work at Pithampur.
- Your Company is having research and development cell headed by a senior and experienced chemist. Continuous observation on the quality of the product at various levels, is being kept by the section. This section also keeps a regular track on latest advancement of the injection technology in order to keep changing with the demand.

Place : Indore Dated : 18th August, 2009 By order of the Board of Directors For Beryl Drugs Limited SD/-(SANJAY SETHI) MANAGING DIRECTOR

CORPORATE GOVERNANCE DISCLOSURE:

The Company pursuant to the clause 49 of the Listing agreement entered with the Stock Exchanges furnishes its report on the code of Corporate Governance as on 31st March 2009.

A) COMPANY'S PHILOSOPHY

The Philosophy on Corporate Governance is implemented in the Company with the Objective of attaining the highest standards of Corporate Governance to respect its fiduciary responsibility to the shareholders. The policies and guidelines of Corporate Governance have been implemented in all facets of its operation to build up an environment of trust and confidence amongst the stakeholders of the Company. The cardinal principal such as independence, accountability, responsibility, transparency, fair and timely disclosures, credibility etc. serve as the means for implementing the philosophy of corporate governance in letter and spirit.

We believe that sound corporate governance is critical to enhance and retain investor trust. Accordingly, we always seek to ensure that we attain our performance with integrity and the Board exercises its fiduciary responsibility in the widest sense of the term

B) BOARD OF DIRECTORS

The Board of Directors of the Company is comprised of:

- Two Executive Director.
- Two non-executive Directors.

Attendance of each Director at the Board meetings, last Annual General Meeting and number of other Directorship and Chairmanship/ membership of Committee of each director in various Companies.

Name of Director	Category	Attendence Particulars		No. of other Directorships and Committe membership / chairmanship		
		Meeting	Last AGM	Other Directorship	Committee Membership	Committee Chairmanship
Mr. Sanjay Sethi	MD	Four	Yes	One	Nil	Nil
Mr. Sudhir Sethi	WTD	Four	Yes	One	Six	Nil
Mr. Sunil Jain	CMNED	Four	Yes	One	Six	Three
Mr. Hemant Jain	NED	Four	Yes	Nil	Six	Nil

MD: Managing Director WTD: Whole time Director

NED: Non Executive Director CMNED: Chairman cum Non Executive Director

Number of Board of Directors Meeting held and the dates on which held

During the year, the Company held the Four Board Meetings as against the minimum requirement of Four meetings on April 21, 2008, July 21, 2008, October 21, 2008, and January 27, 2009. The maximum time gap between two meetings was not exceeding three calendar months.

C) AUDIT COMMITTEE

1. Terms of reference

The Audit Committee is to oversee the Company's financial reporting process and disclosure of its financial information, to review and discuss with the Auditors about internal control system. The scope of audit includes compliance of accounting standards with Listing Agreement; compliance of accounting policies, practice and entries. To review the Company's financial and risk management policies, to review the quarterly, half yearly and annual financial statements before they are submitted to the Board of Directors. Minutes of Audit Committee are circulated to the members of the Board of Directors, discussed, and taken note of it.

16TH ANNUAL REPORT	

2. Composition

The Audit Committee of the Board of Directors comprising two non-executive independent Directors and a whole time Director, Chairman of the committee is on rotational basis. Committee met 4 times during the year and attendance of the members at the meeting was as follows:

Audit Committee meetings were held 4 times in the year and the directors present were:

Name of the Director	Designation	No. of meeting attended
Mr. Sunil Jain	Chairman	4
Mr. Sudhir Sethi	Member	4
Mr. Hemant Jain	Member	4

D) Remuneration committee :

The Board of Directors of the Company has constituted a Remuneration Committee comprising of two independent non-executive Directors Mr. Sunil Jain Chairman, Mr. Hemant Jain and a whole time Director Mr. Sudhir Sethi.

The Remuneration Committee has been constituted to recommend/ review the remuneration package of the Managing/ Whole-time Director based on performance and defined criteria.

The remuneration policy is directed toward rewarding performance, based on review of achievements on a periodical basis. The remuneration policy is in consonance with the existing Industrial Practices.

E) Investors'/ shareholders grievance committee :

1. Term of reference

The Company has designated Shri Devendra Sinha severally to specially look into the redressal of shareholders and investors complaints like transfer of shares, non-receipt of Balance Sheet, non-receipt of dividend and attend investors' complaints received from SEBI, Department of Company Affairs and Stock Exchanges where the securities of the Company are listed in consultation with the committee.

2. Composition

The share Transfer Committee consists of the following:

Name of the Director	Designation
Shri Sunil Jain,	Chairman
Shri Sudhir Sethi	Member
Shri Hemant Jain	Member

During the financial year 2008-09, the committee met 4 times and transacted business concerning the committee. The total number of complaints received and replied to the satisfaction of the shareholders during the year, was Twenty Two and outstanding complaints as on 31.03.2009 were Nil.

F) General body meetings

The last three Annual General Meeting of the company were held as under :

Financial Ye	ar Date	Time	Location
2007-2008	September 30, 2008	10.00 A.M	Kanchan Palace, Community Hall, Nipania, Ring Road, Indore
2006-2007	September 29, 2007	11.00 A.M	Kanchan Palace, Community Hall, Nipania, Ring Road, Indore
2005-2006	September 29, 2006	11.00 A.M	Kanchan Palace, Community Hall, Nipania, Ring Road, Indore

16TH ANNUAL REPORT		

2004-2005 September 26, 2005 11.00 A.M

Kanchan Palace, Community Hall, Nipania, Ring Road, Indore

Note:

No postal ballots were used/ invited for voting at these meetings in respect of any special resolution passed during the year. The company shall comply with the requirements relating to postal ballot as and when the relevant guidelines in this connection will apply on the Company.

G) Disclosures

- 1. During the year, there were no transactions of material nature with the directors or the management or their subsidiaries or relatives that had potential conflict with the interest of the Company.
- 2. The Company has complied with the requirement of the Stock Exchanges/SEBI/and other Statutory Authorities on all maters related to capitals markets during the last three years. No penalties or stricture have been imposed on the Company by the Stock Exchange or SEBI or any statutory authorities

H) Means of communication

The Company uses widely circulated newspaper as a vehicle for communication to shareholders and other concerned persons. The Company's quarterly results in the Performa prescribed by the Stock Exchange are approved and taken on record by the Board within the prescribed time frame and sent forthwith to all Stock Exchanges on which Company's shares are listed. These results are being published in leading newspapers-

- Choutha Sansar in Hindi.
- Free Press in English.

I) Compliance Officer

Mr. Ashish Karodia, Company Secretary, heading the Company Secretaries, is the Compliance officer under SEBI (Regulation to an Issue and Share Transfer Agent) Regulation, 1993 and under clause 47 of the Listing Agreement with Sock Exchange.

J) GENERAL SHAREHOLDERS INFORMATION

Annual General Meeting :	Date: Time :	September 30, 2009. Wednesday 10.00 A.M.
	Venue :	Kanchan Palace, Community Hall, Nipania, Ring Road, Indore - 452 001.

1. Financial Calendar for the year 2008-2009 (Provisional)

For the quarter ended on :

2nd week of July, 2008
2nd week of October, 2008
2nd week of January, 2009
2nd week on April, 2009
30th September 2009

2. Book Closure Dates :

The register of Members and Share Transfer books are closed keeping in view the proposed date of the Annual General Meeting. For the year under reference the above registers/books would be closed from 22nd September 2009 to 30th September 2009 (both days inclusive) and was notified accordingly.

3. Dividend payment date :

Company has not declared any dividend for the year.

4. Listing of Shares :

The Equity Shares issued by the Company are listed on the Bombay Stock Exchange, Madhya Pradesh Stock Exchange & Ahmedabad Stock Exchange.

5 Dematerialization of shares :

The Shares of the company are now in dematerialized form.

BERYL DRUGS LIMITED

16TH ANNUAL REPORT

6. Stock Market Data

The frequency of trading in securities of the Company is very less. The highest and lowest price recorded during the last financial year is:

:

MONTH	(In Rs. Pe	er Share)
MONTH	High Price	Low Price
April, 2008	17.85	13.10
May, 2008	18.00	12.25
June, 2008	19.80	14.05
July, 2008	14.30	10.48
August, 2008	14.33	11.00
September, 2008	13.62	11.50
October, 2008	11.45	10.88
November, 2008	No Trading	No Trading
December, 2008	10.80	10.34
January, 2009	10.75	10.27
February, 2009	No Trading	No Trading
March, 2009	11.00	9.51

7. Registrars, Share Transfer Agent & Shareholders Correspondence

M/s. Adroit Corporate Services (P) Ltd.
19/20, Jaferbhoy, Industrial Estate,
1st Floor Makawana Road, Marol Naka, Andheri (E)
Mumbai, 400 059
Ph. 022 - 28596060, 28594060 Fax - 28503748

8. Shareholding pattern as at 31.03.2009

Category of Shareholders	No. of Shares	% of Total Shares held
Promoter's Holding	13,52,600	26.36
Body Corporate	296350	5.78
Indian Public	3447250	67.18
NRIs/ OCBs	34800	0.68
	51,31,000	100.00

9. Plant Location:

Plot No. 123 & 124, Industrial Area No. 1 Pithampur, Distt. DHAR (M.P.)

10. Share Transfer System

Presently the shares of the company are being traded in dematerialized form.

Auditors' Certificate on compliance of Conditions of Corporate Governance

To, The Members BERYL DRUGS LIMITED Indore

We have examined the compliance of the conditions of Corporate Governance by Beryl Drugs Limited for the year ended on March 31, 2009 as stipulated in Clause 49 of the Listing Agreement of the said Company with Stock Exchange in India.

The compliance of conditions of Corporate Governance is the responsibilities of the management. Our examination has been limited to the procedures and implementation thereof, adopted by the Company for ensuring the Compliance with the conditions of the Corporate Governance. It is neither an audit nor an express of opinion on the financial statement of the Company.

In our opinion and to the best of our information and explanations given to us and the representation made by the management, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in clause 49 of the Listing Agreements.

As required by the guidance notes issued by the ICAI and as per the records maintained by the Shareholders/ Investors Grievance Committee and certified by the Company, we state that during the year ended March 31, 2009, no investor grievances are pending for a period exceeding one month against the Company.

We further state that such Compliance is neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the management has conducted the affairs of the Company.

FOR SUBHASH CHAND JAIN ANURAG & ASSOCIATES Chartered Accountants,

Place : Indore Date : 18th August, 2009

(S.C. JAIN) PARTNER

Company Secretary Certificate on Compliance of condition of Corporate Governance (Certificate for the Year ended 30th September 2008)

To, The Members, Beryl Drugs Limited Indore.

I have examined all relevant transfer books, forms, registers, files, documents and other related records of **BERYL DRUGS LIMITED** (herein referred to as "the Company") having its registered office at 43-44, 2nd Floor, Dawa Bazar, 13-14, R.N.T. Marg, Indore (M.P)-452001 and its Share transfer Agent, for the Six months ended on September 30, 2008 for the purpose of issuing Certificate under sub- clause (C) of Clause 47 of the listing Agreement executed with the Stock Exchange.

On the Basis of our Verification of records and further information and explanation received from the company as were consider necessary for the purpose of issuing this certificate, we hereby certify that the Company has complied with the requirement of issuing.

- a) No. share certificate received for registration of transfer during the period from 01.04.2008 to 30.09.2008.
- b) No.Share Certificate received for sub-division, consolidation and exchange or endorsement of calls/allotments monies , during the period from 01.04.2008 to 30.09.2008.

Place : Indore Date : 16.10.2008 ASHISH KARODIA Company Secretary C.P.No.-6375

Company Secretary Certificate on Compliance of condition of Corporate Governance (Certificate for the Year ended 31st March 2009)

To, The Members, Beryl Drugs Limited Indore.

I have examined all relevant transfer books, forms, registers, files, documents and other related records of **BERYL DRUGS LIMITED** (herein referred to as "the Company") having its registered office at 43-44, 2nd Floor, Dawa Bazar, 13-14, R.N.T. Marg, Indore (M.P)-452001 and its Share transfer Agent, for the Six months ended on March 31, 2009 for the purpose of issuing Certificate under sub- clause (C) of Clause 47 of the listing Agreement executed with the Stock Exchange.

On the Basis of our Verification of records and further information and explanation received from the company as were consider necessary for the purpose of issuing this certificate, we hereby certify that the Company has complied with the requirement of issuing.

- a) All the share certificate issued for Registration of Transfer within one month of the date of lodgment for transfer excepting those rejecting on technical grounds.
- b) All the Share Certificate received for sub-division, consolidation and exchange or endorsement of calls / allotments monies, issued within one month of the Date of lodgment of the company.

Place : Indoré Date : 20.04.2009 ASHISH KARODIA Company Secretary C.P.No.-6375

AUDITORS REPORT

To THE MEMBERS BERYL DRUGS LTD.

- 1. We have audited the attached Balance Sheet of Beryl Drugs Ltd. as at 31st March 2009 and also the Profit and Loss Account and the Cash Flow statement of the Company for the year ended on that date annexed thereto, These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audit.
- 2. We conducted our audit in accordance with auditing standards generally accepted in India. Those Standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test check, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.
- 3. As required by the Companies (Auditor's Report) Order, 2003 (CARO) issued by the Central Government of India in terms of section 227 (4A) of the Companies Act, 1956 and on the basis of such checks of the books and records as we considered necessary and appropriate and according to the information and explanation given to us during the course of the audit, we enclose in the Annexure, a statement on the matters specified in paragraphs 4 and 5 of the said order.
- 4. Further to our comments in the Annexure referred to in paragraph 3 above, we report that:
 - (a) we have obtained all the information and explanations, which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - (b) in our opinion, proper books of accounts as required by law have been kept by the Company so far as appears from our examination of such books.
 - (c) the Balance Sheet, Profit and Loss Account and Cash Flow Statement dealt with by this report are in agreement with the books of accounts.
 - (d) in our opinion, the Balance Sheet, Profit and Loss Account and Cash Flow Statement dealt with by this report comply with the Accounting Standards referred to in sub-section (3C) of section 211 of the Companies Act, 1956. That Company has not quantified / provided the amount of gratuity and accrued leave encashment as on 31.03.2009 as required as per "Accounting Standard " (AS) 15" (Revised 2005) of Institute of Chartered Accountants of India.

That Company has not provided diminution is value of share of subsidiary company Rs. 61.06 lakhs and to that extent profit and investment is subsidiary is overstarted.

- (e) on the basis of the written representations received from the directors and taken on record by the Board of Directors, we report that none of the directors are disqualified as on 31st March, 2009 from being appointed as a director in terms of clause (g) of sub section (1) of section 274 of the Companies Act, 1956.
- 5. In our opinion and to the best of our information and according to the explanations given to us, the said financial statement read with significant accounting policies and notes forming part of Schedule "22" and these appearing elsewhere in the accounts, give the information as required by the Companies Act, 1956, in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:
 - (i) in the case of the Balance Sheet of the state of affairs of the Company as at 31st March, 2009;
 - (ii) in the case of Profit and Loss Account of the profit for the year ended on that date, and
 - (iii) in the case of Cash Flow Statement, of the cash flows for the year ended on that date.

For SUBHASH CHAND JAIN ANURAG & ASSOCIATES

Chartered Accountants,

Place : Indore (M.P.) Date : August 18th, 2009 (S.C. JAIN) PARTNER MNO. 72062

ANNEXURE TO THE AUDITOR'S REPORT

Annexure as referred to in paragraph third of our Report of even date to the members of Beryl Drugs Limited on the accounts for the year ended 31st March, 2009.

(i) Fixed Assets

- (a) As informed to us that, the Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets.
- (b) As informed to us that, the management has physically verified fixed assets of the company during the year at reasonable intervals. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
- (c) In our opinion and according to the information and explanations given to us, the Company has not disposed off a substantial part of fixed assets during the year hence the going concern status of the company is not affected.

(ii) Inventories

- (a) As explained to us, physical verification of inventories has been conducted during the year by the management at reasonable interval.
- (b) In our opinion and according to the information and explanations given to us, the procedures of physical verification of inventories followed by the management are reasonable and adequate in relation to the size of the Company and the nature of its business.
- (c) On the basis of our examination of the records of inventory we are of the opinion that the Company has maintained proper records of its inventories and no material discrepancies were noticed on physical verification. However, if any discrepancies noticed the same has been properly dealt with in the books of account.

(iii) Loan Granted or Taken

- (a) The Company has not given any secured or unsecured loan to companies or other parties covered in the register maintained under section 301 of the Companies Act, 1956.
- (b) As per information and explanations given to us, the company has not taken any Unsecured Loan except Rs. 33000/- taken from one company which is covered in the register maintained under Section 301 of the Companies Act, 1956. The Balance out standing as at Balance sheet is Rs. 33000/- (Previous year Rs, Nil)
- (c) In our opinion and according to the information and explanation given to us the Term & condition on which loan have been taken are not prima facie prejudicial to interest of the company.
- (d) As informed to us no Term & Condition is fixed for repayment of the loan obtained because same is repayable on demand, in view of the above no amount is over due.

(iv) Internal Control Procedure

In our opinion and according to the information and explanations given to us, there are adequate internal control procedures commensurate with the size of the Company and the nature of its business with regard to the purchase of fixed assets and sales of goods. During the course of audit, no major weakness has been notices in the internal control system in respect of these areas.

(v) Transaction with Parties u/s 301

- a) In our opinion and according to the information and explanation given to us, based on the disclosure of interest made by the director of the company, contract or arrangement that need to be entered into the register maintained under sec. 301 of the Companies Act, 1956 have been so entered.
- b) Based on the audit procedures applied by us and according to information and explanation provided by the management, there are no transaction exceeding the value of Rs. 5 Lacs made in pursuance of contract or agreement entered into the register maintained under section 301 of the Companies Act, 1956 in during the year.

(vi) Public Deposit

	16TH	I ANNU	AL REPORT				BERYL	DRUGS LIMITED
	nor		any deposits					npany neither accepted ies Act, 1956 and rules
(vii)	Inte	ernal Au	dit System					
		•	on, the Com business.	pany has a	an adequate in	ternal audit sys	tem commensurate	e with the size and the
(viii) Cos	st Recoi	ď					
								st record under section the year under review
(ix)	Sta	tutory D)ues					
	(a)	books of Fund, E other m given to	of accounts, t Employee Sta aterial statute us there are nding as at 3	he compar ate Insuran ory dues wi no undispu	ny is regular, in ice, Income Ta ith the appropri ited amount pay	depositing undi x, Wealth Tax, ate authority. Ac yable in respact o	sputed statutory du Custom Duty, Exc cording to the infor of such statuory due	our examination of the ues including Provident ise Duty and Cess and mation and explanation as which have remained the day they become
	(b) According to the information and explanation given to us, there were no disputed amount payable ir respact of sales tax / excise duty / wealth tax / service tax except following which neither was paid as or date nor provided in the books of accounts for same amount.							
		S.No.	Name of th	e statute	Nature of Dues	Amount (Rs.)	Period to which the amount relates	Forum where dispute pending

1. M.P. Entry Tax Entry Tax 82865.00 98-99 **Revision filed** on car before Addl. Commissioner of Commercial Tax Indore. 2. 327190.00 Central Excise Central 00-01 **Central Excise &** Service Tax Excise Appellate Tribunal

(x) Accumulated Cash losses

The Company neither have any accumulated losses at the end of the current financial year, nor incurred cash losses during the current and immediately preceding financial year.

(xi) Default in repayment of dues to Financial Institutions or Bank

Based on our audit procedures and on the information and explanations given by the management, we are of the opinion that the company has not defaulted in the repayment of dues to banks with respect to its borrowings.

(xii) Granting of Loan and Advances

According to the information and explanations given to us, the Company has not given any loans and advances on the basis of security by way of pledge of shares, debentures and other securities.

(xiii) Chit Fund/Nidhi/Mutual Benefit Fund/Society Activities

In our opinion, the company is not Chit Fund or a Nidhi/Mutual Benefit Fund Society. Therefore, the said clause is not applicable to the Company.

(xiv) Dealing or Trading in Shares

According to the information and explanation given to us, the company is not dealing or trading in share securities, debentures and others, accordingly the provision of said clause are not applicable to the company.

(xv) Guarantee given by the Company for loan taken by others

As informed and explained to us the Company has not given any guarantee in respect of loans taken by others from any bank or financial institutions.

(xvi) Utilization of Term Loan

As per information and explanation given to us, the company has not taken any term loan during the year hence comments regarding utilization of term loan does not applicable.

(xvii) Application of Short Term Fund for Long Term Investment and vice versa

On the basis of examination and information and explanations given to us, the company has not used the funds borrowed on short term basis for long term investment.

(xviii) Preferential Allotment of Shares

We are informed that, the Company has not made any preferential allotment of shares to the parties listed in the Register maintained under section 301 of the Act.

(xix) Creation of Securities for Debenture Issue

According to the information and explanations given to us and the records examined by us, the company has not issued any debenture hence requirement of disclosure regarding creation of securities in respect of debentures issued does not arises.

(xx) Money raised by Public Issue

The Company has not raised any money by public issue of shares during the year and therefore, the question of disclosing the end use of money does not arise.

(xxi) Fraud noticed or Reported

To the best of our knowledge and belief and according to the information and explanations given to us, no fraud on or by the Company was noticed or reported during the course of our audit.

For SUBHASH CHAND JAIN ANURAG & ASSOCIATES Chartered Accountants

Place : Indore Date : 18th August, 2009

(S.C. JAIN) PARTNER MNO. 72062

BALANCE SHEET AS ON 31ST MARCH, 2009

S.NC). PARTICULARS	REFER		CURRENT YEA AS AT 31-03-20		PREVIOUS YEAR AS AT 31-03-2008
I) S				<u> </u>		, ,
	 A) SHAREHOLDERS FUND 1 SHARE CAPITAL 2. RESERVE & SURPLUS 	"01" "02"		50594000.00 4752219.52		50397050.00 4600221.92
	(B) LOAN FUNDS 1 SECURED LOANS 2 UNSECURED LOANS	"03" "04"		9304684.44 195812.00		7560580.92 471452.00
	GRAND TOTAL	•		64846715.96		63029304.84
11.	APPLICATION OF FUNDS				:	
	 a) FIXED ASSETS (a) GROSS BLOCK (b) LESS: DEPRECIATION 	"05"	67738603.12 41451634.43		64350365.31 37994728.88	
	 (c)NET BLOCK 2 CAPITAL WORK IN PROGRES 3 DEFERRED TAX ASSETS 4 INVESTMENTS 5 CURRENT ASSETS, LOANS & ADVANCES 	"06"		26286968.69 10000.00 1023712.48 6784000.00		26355636.43 Nil 902960.10 6784000.00
	(a)INVENTORIES (b)SUNDRY DEBTORS (c)CASH & BANK BALANCES (d)LOANS, ADVANCES &	"07" "08" "09" "10"	12814127.66 18314676.65 1452458.16 8934754.75		14311898.01 11832203.86 578578.14 11245118.32	
	DEPOSITS LESS: CURRENT LIABILITIES & PROVISIONS (e)NET CURRENT ASSETS 6 MISC. EXPENDITURE (TO THE EXTENT NOT WRITT OFF OR ADJUSTED)		41516017.22 10773982.43		37967798.33 8981090.02	28986708.31 NIL
	GRAND TOTAL			64846715.96		63029304.84
	IFICANT ACCOUNTING POLICIES &	"22"		=ucc=========		# # =====##############################
PART IN TE EVEN FOR CHAF	SCHEDUEL REFERRED TO ABOVE FO OF THE BALANCE SHEET RMS OF OUR SEPARATE REPORT O I DATE ATTACHED, SUBHASH CHAND JAIN ANURAG & A RTERED ACCOUNTANTS (S.C. JAIN) PARTNER (MNO. 72062) E : INDORE	F		WE CERTIFY TO T FOR AND ON B (MANAGING DI PLACE : INDOF	EHALF OF THE	BOARD
	E:INDORE :18th August, 2009			PLACE : INDOF DATE : 18th Au		

	16TH ANNUAL REPORT		BERL	
	PROFIT & LOSS A	CCOUNT FOR	THE YEAR ENDED	31/03/2009
S.NO	D. PARTICULARS	REFERRED SCHEDULE	CURRENT YEAR ENDED 31-03-2009	PREVIOUS YEAR ENDED 31-03-2008
	INCOME	#10#	60041000.00	C0059400.07
	1 SALES 2 OTHER INCOME	"12" "13"	69841029.82 240658.35	62258420.07 779112.02
	3 INCREASE/(DECREASE) IN STOCK	"14"	446888.10	2637547.00
		TOTAL (A)	70528576.27	65675079.09
В.	EXPENDITURE			
	1 MATERIAL CONSUMED	"15"	46535806.21	41675266.34
	2 MANUFACTURING EXPENSES	"16"	8891457.09	8004570.50
	3 ADMINISTRATIVE & ESTABL. EXP.	"17"	2683021.89	2921172.14
	4 EMPLOYEES REMUNERATION & E	BENEFITS"18"	3938151.00	2849846.00
	5 SELLING & DISTRIBUTION EXPEN		3694911.58	4570356.46
	6 INTEREST & FINANCIAL CHARGES	S "20"	1232257.78	1325988.90
	8 DEPRECIATON		3266325.75	3594216.42
		TOTAL (B)	70241931.30	64941416.76
	NET PROFIT (BEFORE PRIOR PERIOD ADJUSTMEN	(A-B)	======================================	733662.33
	PRIOR PERIOD ADJUSTMENT	"21"	5776 00	281164.00
	NET PROFIT (BEFORE TAX)	21	5776.00 280868.97	452498.33
F	PROVISION FOR TAX			
	i) CURRENT TAX	207541.14		637310.00
	ii) FRINGE BENEFIT TAX	42082.86		144423.00
	iii) DEFERRED TAX LIABILITY (ASSETS) —	(-) 120752.62	(-)) 344286.28
	(ASSETS)		128871.38	437446.72
G	NET PROFIT (AFTER TAX)		151997.59	15051.61
Н	PROVISION OF TAX OF EARLIER YEAF WRITTEN BACK	7	Nil	217050.00
	PROFIT BALANCE BROUGHT FORWAF FROM PREVIOUS YEAR		4121519.93	3889418.32
	ACCUMULATED BALANCE CARRIED		4273517.52	4121519.93
	EARNING PER SHARE (BASIC/DILUTEI SIGNIFICANT ACCOUNTING POLICIES		0.03	0.003
	NOTES TO ACCOUNTS	"22"		
	IN TERMS OF OUR SEPARATE REPOR EVEN DATE ATTACHED,	_		
FOR	SUBHASH CHAND JAIN ANURAG & A			ORRECTNESS OF ABOVE, N BEHALF OF THE BOARD
CHA	RTERED ACCOUNTANTS			
1	(S.C. JAIN) PARTNER M.NO. 72062		(MANAGING DIRE	CTOR) (DIRECTOR)
PLA	CE : INDORE	F	PLACE : INDORE	
	E:18th August, 2009		DATE : 18th August, 2	2009
			· •	
_		21		

SCHEDULE FORMING PART OF BALANCE SHEET FO S. No. PARTICULAR	AMOUNT AS ON 31-03-2009	AMOUNT AS ON 31-03-2008
SCHEDULE "01" SHARE CAPITAL		· · · · · · · · · · · · · · · · · · ·
A) AUTHORISED SHARE CAPITAL 10000000 EQUITY SHARES OF RS.10/- EACH	10000000.00	10000000.00
B) ISSUED, SUBSCRIBED & PAID UP CAPITAL 5131000 EQUITY SHARES @RS.10/- EACH LESS: CALLS IN ARREARS	51310000.00 716000.00	51310000.00 912950.00
τοται	50594000.00	50397050.00
SCHEDULE "02" RESERVE & SURPLUS 1. SURPLUS OF PROFIT & LOSS ACCOUNT 2. STATE CAPITAL SUBSIDY TOTAL SCHEDULE "03"	4273517.52 478702.00 4752219.52	4121519.92 478702.00 4600221.92
SECURED LOANS A) WORKING CAPITAL LOAN PUNJAB NATIONAL BANK, MANORAMAGANJ BRANCH, INDORE (SECURED AGAINST HYPOTHECATION OF STOCK OF RAW MATERIAL, PACKING MATERIAL, FINISHED GOODS, CONSUMABLE STORES AND SPARES, BILLS, RECEIVABLE BOOKS DEBTS & ALL OTHER MOVABLE BOTH PRESENT & FUTURE)	9304684.44	7560580.92
ΤΟΤΑΙ	9304684.44	7560580.92
SCHEDULE "04" UNSECURED LOANS 1. FROM ICICI, INDORE (CAR LOAN) 2. PNB MANORAMAGANJ BR (AGAINST FDR)		========= 471452.00 Nil
τοται	195812.00	471452.00

SCHEDULE "05"

FIXED ASSETS (AT COST)

S.No	. PARTICUAL	.RS	GROSS BI	LOCK	D	EPRECIAT	ION		N	ET BLOCK	Κ
		VALUE	ADDITION	DEDUCTION	TOTAL	UP TO	FOR THE	DEDUCTION	TOTAL.	AS ON	AS ON
		AS AT	DURING	DURING THE	AS AT	31.03.2008	YEAR	DURING THE		31.03.2009	31.03.2008
		01.04.2008	THE YEAR	YEAR	31.03.2009			YEAR			
16	LOCK & DESIGN	88740.00			88740.00	68536.34	2810.32		71346.66	17393.34	20203.66
2 F	URNITURE	1212074.53	•• .		1212074.53	874513.63	61098.52		935612.15	276462.38	337560.90
3 E	LECTRIC INSTALLATION	1917364.76			1917364.76	1699669.21	30281.45		1729950.66	187414.10	217695.55
4 (FFICE EQUIPMENTS	193373.00	10682.00		204055.00	125598.12	10308.53		135906.65	68148.35	67774.88
5 ۱	EHICLES	3424929.91			3424929.91	1639773.36	462177.03		2101950.39	1322979.52	1785156.55
6 L	AND	2362814.00			2362814.00					2362814.00	2362814.00
7 1	DMN. OFFICE AT	529254.00	••		529254.00	278111.92	12557.10		290669.02	238584.98	251142.08
C	AWA BAZAR										
8 5	IGN BOARD	0.00		**	0.00	0.00	0.00		0.00		0.00
94	IR CONDITIONER	85915.00	27742.00		113657.00	39236.32	10098.17		49334.49	64322.51	46678.68
10 8	LANT & MACHINERY	17288793.56	2397269.81		19686063.37	10772655.04	984910.24		11757565.28	7928498.09	6516138.53
11 F	ACTORY BUILDING	20413530.94	468623.00	-	20882153.94	11902474.27	873274.61		12775748.88	8106405.06	8511056.63
12 L	AB EQUIPMENTS	555882.00	0.00	-	555882.00	319909.47	32823.77		352733.24	203148.76	235972.53
	THER PLANT &	13829904.83	275991.00		14105895.83	9873215.02	604776.29	-	10477991.31	3627904.52	3956689.8
14 (OMPUTER & PRINTER	404100.00	3000.00	-	407100.00	310494.79	37844.59		348339.38	58760.62	93605.2
15 I	NOBILE INSTRUMENT	84803.00	14350.00	-	99153.00	51002.68	16224.99		67227.67	31925.33	33800.33
17 L	EASEHOLD LAND	182305.78			182305.78					182305.78	182305.78
18 5	TE DEVELOPMENT	1501520.00			1501520.00	230118.51	127140.14		357258.65	1144261.35	1271401.49
19 L	AND FOR GODOWN	465640.00		-	465640.00			••		465640.00	465640.00
TOTA	L CURRENT YEAR	64540945.31	3197657.81	0.00	87738603.12	38185308.68	3266325.75		41451634.43	26286968.69	26355636.63
TOTA	L PREVIOUS YEAR	60296460.33	4053904.98	0.00	64350365.31	34400512.46	3594216.42	••	37994728.88	26355636.43	26361587.87

	16TH ANNUAL REPORT		BER		
== sc	LE				
	/ESTMENTS				
	COST)				
<u>S.N</u>	IO. PARTICULARS		AMOUNT		AMOUNT
			AS ON		AS ON
			31.03.2009		31.03.2008
Α.	QUOTED (LONG TERM)		0704000.00		0704000 00
	1 EQUITY SHARES IN BERYL SECURITIES LTD.		6784000.00		6784000.00
	(678400 EQUITY SHARES OF R	S.10/- EACH FULLY P	AID-UP)		,
	MARKET VALUE RS.678400.00				
		TOTAL	6784000.00		6784000.00
		IUIAL	============		===========
sc	HEDULE "07"	•			
IN۱	/ENTORIES				
1	RAW MATERIAL		1348595.68		1263433.17
2 3	PACKING MATERIAL FINISHED GOODS	·	4725340.24 6740191.74		6755161.84
3	FINISHED GOODS		6740191.74		6293303.00
		TOTAL	12814127.66		14311898.01
~ ~					==========
	HEDULE "08" NDRY DEBTORS	· .			
	SECURED CONSIDERED GOOD)				
(О. А.	OUTSTANDING EXCEEDING SIX M		6855095.00		8256517.00
В.	OTHERS		11459581.65		3575686.86
Б.	UTHENS .		11459561.05		35/3686.86
		TOTAL (A + B)	18314676.65		11832203.86
sc	HEDULE "09"		**********		
	SH & BANK BALANCE				
Α.	CASH IN HAND		38194.69		352058.95
B.	BANK BALANCE WITH SCHEDULE	D BANK			
1	CURRENT ACCOUNT	448394.47		226519.19	
2	FIXED DEPOSIT ACCOUNT	965869.00		Nil	
			· ,		
	· · · · ·		1414263.47		226519.19

24

Ξ

16TH ANNUAL REPORT	BERYL	DRUGS LIMITED
S.NO. PARTICULARS	AMOUNT AS ON	AMOUNT AS ON
	31.03.2009	31.03.2008
SCHEDULE "10"		
LOANS, ADVANCE & DEPOSITS		
(UNSECURED CONSIDERED GOOD)		
A DEPOSIT WITH GOVT. AUTHORITIES & OTHERS	1343411.00	1047731.00
B ADVANCE RECOVERABLE IN CASH OR IN KIND	7416817.75	10053886.32
OR FOR VALUE TO BE RECEIVED		
C ADVANCE INCOME TAX & TDS	174526.00	143501.00
D VAT. CREDIT ENTILEMENT	Nil	41562.00
TOTAL (A + B + C + D)	8934754.75	11286680.32
SCHEDULE "11"		
CURRENT LIABILITIES & PROVISIONS		1 101 100 75
A. CREDITORS FOR UNPAID EXPENSES	1393285.30	1481106.75
B. CREDITORS FOR GOODS, SUPPLY & OTHERS	7908867.63	5063389.96
C. ADVANCE RECEIVED FROM CUSTOMERS	376026.00	1257003.85
D. CREDITORS FOR PROVISIONS	1095803.50	1179589.46
TOTAL (A + B + C + D)	10773982.43	8981090.02
		=========

BERYL DRUGS LIMITED

SCHEDULE FORMING PART OF PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH, 2009.

S. PARTIC	JLAR		YEAR ENDED	······································	YEAR ENDED
No.			31.03.2009		31.03.2008
SCHEDULE "	12"				• • • •
<u>SALES</u>					
	BLE (LOCAL)	14701123.42		12631823.39	
2 INJECTA	BLE (INTER-STATE)	14639077.50		9312330.00	
3 INJECTA LOCAL	BLE (GOVERNENT DEPT.)	3671009.60		6518917.68	
CONSIG	NMENT	36877239.00		34253096.00	
5 EXPORT		420000.00		348000.00	
SOS		169605.30		Nil	
			70478054.82		63064167.07
<u>LESS : S</u>	ALES RETURN				
1 LOCA	NL .	91984.00		56370.00	
2 INTE	R STATE	194377.00		145150.00	
3 GOV	Г. DEPT.	Nil		221772.00	
4 DISC		2279.00		Nil	
			288640.00		423292.00
			70189414.82		62640875.07
ESS: EXCIS	E DUTY (INCLUDING CESS)		348385.00		382455.00
		TOTAL	69841029.82		62258420.07
CHEDULE "					
DTHER INCO RENT RE			48000.00		48000.00
	D INTEREST ON FDR		11989.00		2284.00
	FROM OTHERS		16819.00		162.00
			163850.35		511919.02
			NIL		2941.00
UNCLAIN	IED LIABILITY		NIL		213806.00
		TOTAL	240658.35		779112.02
	4 4 11				=R==#25====
	-				
	STOCK (FINISHED GOODS)		6740191.10		6293303.00
	PENING STOCK (FINISHED GC	DODS)	6293303.00		3655756.00
		TOTAL	446888.10		2637547.00
			========		==========

			· · · · · · · · · · · · · · · · · · ·		
S. 1	No. PARTICULAR		YEAR ENDED 31-03-2009		YEAR ENDE
sc	HEDULE "15"				
MA	TERIAL CONSUMED				
A	RAW MATERIAL CONSUMED				
	1 OPENING STOCK	1263432.80		2126146.00	
	ADD: PURCHASES	9197236.38		6900701 10	
	(a) LOCAL (b) OUT OF M.P.	3986102.95		6802721.13 1752960.00	
	ADD: INPUT REBATE REVERSE	598421.15		498789.42	
	AGAINST CONSIGNMENT SALE	000421.10		490709.42	
		15045193.28		11180616.55	
	LESS: PURCHASE RATE DIFFERENCE	32886.00		Nil	
	LESS PURCHASE RETURN LESS: EXCISE CENVAT ON RAW	219057.00		Nil	
	MATERIAL PURCHASES	602749.00		175818.00	
	LESS: CLOSING STOCK	1348595.68		1263432.80	
		2203287.68		1439250.80	
			12841905.60		9741365.7
В	PACKING MATERIAL CONSUME	C			
	OPENING STOCK	6755161.84		4327415.00	
	ADD: PURCHASES	10060050.01		10010005-00	
	(a) LOCAL (b) OUT OF M.P.	19969252.91 11711182.10		16612685.68 17830409.75	
				17830409.75	
		38435596.85	•	38770510.43	
	LESS: RETURN OF PACKING MAT			10150.00	
	1. LOCAL LESS: EXCISE CENVAT ON	Nil		18150.00	
	PACKING MATERIAL	16356.00		63298.00	
	LESS: CLOSING STOCK	38419240.85 4725340.24		38689062.43 6755161.84	
			33693900.61		31933900.5
	TOTAL MATERIAL CONSUME	D (A+B)	46535806.21		41675266.34
	HEDULE "16" NUFACTURING EXPENSES				
1	CONSUMABLE GOODS & CHEMIC	CALS	1137109.00		924280.50
2	POWER & FUEL EXPENSES	-	4683999.00		4358341.0
3	GAS CHARGES		13469.00		10764.0
4	TESTING CHARGES	-	80486.00		56842.0
5	WATER CHARGES		90607.00		92387.00
6	FREIGHT INWARD		898360.00		877114.00

	16TH ANNUAL REPORT			BERYL	
7	LEASE RENT		24255.00		20713.00
9	LABOUR WELFARE EXPENSES		73581.00		29798.00
10	RATE DIFFERENCE PURCHASE		1729.09		Nil
11	REPAIRS & MAINTENANCE				
	a. MACHINERY		824797.00		519385.00
	b. BUILDING		357734.00		259880.00
	c. ELECTRIC & FITTINGS		190447.00		90431.00
	d. BOILER		56755.00		86698.00
	e. FURNITURE		Nil		900.00
	f. WASHING CHARGES		Nil		440631.00
12	JOB PROCESSING CHARGES		435129.00		219856.00
13	AMC EXPENSES		23000.00		16550.00
	τοτ	TAL	8891457.09		8004570.50
50	HEDULE "17"				
	MINISTRATIVE & ESTABLISHMENT				
1	SECRETARIAL & CERTIFICATION FEE		· Nil		17500.00
2	SECURITY EXPENSES		93960.00		82864.00
3	METADOR EXPENSES		293255.00		156000.00
4	GARDEN EXPENSES		27255.00		16860.00
5	A.G.M. EXPENSES		16000.00		16000.00
6	CONSULTANCY EXPENSES		42500.00		27000.00
7	CONVEYANCE EXPENSES		9755.00		248108.00
8	DIWALI EXPENSES		27795.00		25751.00
9	ELECTRICITY EXPENSES		46855.00		60283.00
10	INSURANCE EXPENSES		710169.00		132704.00
11	LEGAL EXPENSES & PROFESSIONAL EXP.		107234.00	•	148810.00
12	LISTING FEES		16625.00		35000.00
13	MEDICAL EXPENSES		2370.00		5249.00
14	OFFICE EXPENSES		71204.00		66360.00
15	CAR REPAIRS & MAINTENANCE		91276.00		117369.00
16	POSTAGE EXPENSES		76817.22		87582.00
17	REGISTRATION & LICENSE FEES		65071.00		327022.00
21	STATIONERY EXPENSES		56106.00		80831.00
22	TELEPHONE EXPENSES		101251.67		110796.14
23	TOLL TAX		21347.00	· .	27235.00
24	TRAVELLING EXPENSES		141993.00		111877.00
25	AUDITORS REMUNERATION		33090.00		30000.00
26	PROFESSIONAL TAX		2500.00		2500.00
27	PROPERTY TAX		9187.00		9185.00
28	SERVICE TAX		69512.00		71415.00
29	ENTRY TAX		421201.00		486290.00
30	BOOKS & PERIODICALS		Nil		2100.00
31	WEIGHT AND MEASUREMENT EXP.		7442.00		7256.00
32	SOFTWARE EXPENSES		Nil		7500.00
			28		

DRUGS LIMITED	BERYL		6TH ANNUAL REPORT
4155.00		11620.00	COMPUTOR EXP.
50000.00		51220.00	EMAT EXPENSES
66632.00		Nil	OREIGN TRAVELLING Exp.
196510.00		Nil	THER RETIERMENT BENEFITS
N		5000.00	1EMBERSHIP FEES
N		18600.00	VEBSITE DESIGN
11236.00		11236.00	CUSTODIAL FEES
75192.00		Nil	TATUTORY DEMAND 1) EXCISE DUTY
75152.00 N		23575.00	COMMISSION CHARGES
2921172.14		2683021.89	TOTAL
=======================================			
1000510.00		0007000 00	OYEES REMUNERATION & BENEFITS
1939510.00		2837280.00	
135304.00		227819.00	
111516.00		150807.00	CONTRIBUTION TO PROVIDENT FUND
17563.00		12008.00	ASH TO PF (EMPLOYEE)
45953.00		59215.00	SI CONTRIBUTION (EMPLOYER)
600000.00		600000.00	DIRECTORS REMUNERATION
Ni		19110.00	EAVE ENCASHMENT EXP
Ni		31912.00	SIC EMPLOYEE
2849846.00		3938151.00	TOTAL
			NG & DISTRIBUTION EXPENSES
1662690.18		1542276.58	REIGHT OUTWARD
18250.00		25000.00	DVERTISEMENT
1292410.00		1297786.00	OMMISSION ON SALE
25714.00		13653.15	ALES PROMOTION EXP.
432477.85		134557.85	DISCOUNT ALLOWED
715941.08		30422.00	ACKING EXPENSES
59469.35		136538.00	HORTAGE & BREAKAGE
			ENDER EXPENSES
22450.00		24075.00	ARTAGE & HAMMALI EXP.
6001F 00		105802.00	
62915.00		318039.00	ENTRAL SALES TAX ATE DIFFERENCE IN SALE (47562+19200)
278039.00		66762 00	
		66762.00	
278039.00 Ni 4570356.4 6		3694911.58	TOTAL
278039.00 Ni		<u> </u>	TOTAL
278039.00 Ni 4570356.4 6		3694911.58	TOTAL DULE "22" REST & FINANCE CHARGES
278039.00 Ni 4570356.4 6		3694911.58	TOTAL

16TH ANNUAL REPORT	BCR	
TOTAL	1232257.78	1325988.90
SCHEDULE "21" PRIOR PERIOD ITEMS		
A <u>EXPENSES</u>		
1 CERTIFICATE EXPENSES	Nil	122000.00
2 CST AFTER REVISION 05-06	Nil	34656.00
3 SALES TAX AFTER ODER (04-05)	Nil	2000.00
4 CENTRAL TAX AFTER REVISION 05-06	3276.00	122508.00
5 PROFESSIONAL TAX	2500.00	Nil
TOTAL	5776.00	281164.00
	*====	

 π^{s}

30

-

SCHEDULE "22"

SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO THE ACCOUNTS FOR THE YEAR ENDED 31ST MARCH. 2009

(I) SIGNIFICANT ACCOUNTING POLICIES

A. Accounting Convention

a. Basis of Accounting

- The accounts of the Company are prepared under the historical cost convention and in accordance with the applicable Accounting Principle in India, The Accounting Standards issued by the Institute of Chartered Accountants of India and the relevant provision of the Companies Act, 1956. Accounting policies not specifically referred otherwise are in consistence with generally accepted accounting principles followed by the Company.
- The Company follows mercantile system of accounting and recognizes income and expenditure on accrual basis.

b. Sales

Sales are inclusive of freight and octroi claimed in the sales invoices, but net of excise duty and sales return.

C. State Subsidy

State capital investment subsidy not specifically related to any Fixed Assets hance it has been credited to Capital Subsidy Account.

d. Fixed Assets

Fixed assets are stated at cost of acquisition or construction (net of CENVAT where applicable). They are stated at historical cost less accumulated depreciation

e. Depreciation

Depreciation is provided on the basis of Written Down Value method at the rates and in the manner prescribed under Schedule XIV to the Companies Act, 1956.

f. Stores and Spares including Chemical

Stores, Spares & Chemical are charged to the Profit and Loss Account as and when these are incurred.

g. Revenue Recognition

In appropriate circumstances revenue income is recognized when no significant uncertainty as to the determination or realization exist.

h. Inventories

Inventories consisting of Raw Material and Packing Material, have been valued at cost based on FIFO method. Finished goods have been valued at lower of cost or net realisable value. Costs for Finished Goods includes direct material, labour, excise duty and appropriate production overheads

i. Investment

Investment in Equity Shares is stated at cost Company has made the investment amounting to Rs.67.84 lacs (P.Y. Rs.67.84 lacs) in Beryl Securities Ltd. a Company under the same management. But no provision of Rs. 6105600.00 (P.Y. Rs. 55,96,800.00) is made for diminution in value of securities due to temporary in nature in the opinion of the management.

j. Foreign Currency Transactions

There is no foreign currency transaction recorded during the year.

k. Borrowing Cost

Borrowing cost are treated as revenue expenditure and are charged to the Profit and Loss Account for the

3.

	The second s	1			
	16TH ANNUAL REPORT			DRUCCI	
_	TOLL ANNOAL KELOKI			DRUGSL	

year. There is no borrowing cost regarding acquisition of capital assets.

I. Segment Reporting

Since the company is being operated in a single segment, namely "Injectable" (SV & LV) Thus the disclosure requirement of AS-17 issued by the ICAI is not applicable.

m. Taxation

- a) Current Tax is determined as the amount of tax payable in respect of taxable income for the period.
- b) Deferred tax is recognised for future tax consequences of timing differences. It is measured using enacted tax rates and tax laws applicable to taxable income of the current year.
- c) Fringe Benefit Tax determined in accordance with the provision as per sec 115WA &115WB of the Income Tax Act.

n. Earning per share

The company reports basic and diluted Earning Per Shares (EPS) in accordance with AS-20. Basic EPS is computed by dividing the Net Profit after tax for the year by the weighted Average number of Equity Shares outstanding during the year.

o. Retirement Benefit

The disclosure required as per AS-15 "Employee Benefit" issued by the institution of chartered accountants of India (ICAI) and notified under the companies accounts Amended rules 2006 and based on management report as under.

- 1. Company's contribution to Provident Fund and ESI was made during the year as per Employees Provident Fund and Misc. Provision Act, 1952 and ESI Act 1948 respectively as amended from time to time and the same amount has been charged to the Profit & Loss Account.
- 2. Further the Management has not recognize the gratuity in during the year because no employee has retired / left in during the year. However Management explained that the same shall be made on cash basis as and when the eligible employee leaves the Company.
- 3 Leave encashment does not form part of the Retirement Benefit to the employee and therefore the same is not provided for.
- 4. Further the impact of AS-15 (Revised), in respect of employee benefits whose provision have not yet been provided due to pending final calculation & such liabilities could not be quantified due to following reasons.
 - a) The company has not taken group gratuity and cash accumulation policy from life insurance corporation of India (LIC) even having the employee.
 - b) The Company has not calculated the gratuity amount due to explained as same will be recorded on payment basis.

p. Provision Contingent Liabilities& Contingent Assets

A Provision is recognized when the company has a present obligation as a results of past events and it is probable that there will be an outflow of resources would be required to settle the obligation and in respect of which a reliable estimate can be made. Contingent liabilities are not recognised, but are disclosed in the notes, Contingent assets are neither recognized nor disclosed in the financial statement.

q. Cenvat Benefit

CENVAT Benefit is accounted on accrual basis on purchase of Raw material, and Packing Material as per amended rules and regulation.

r. Prior Period Adjustment & Extra Ordinary Item

All identifiable item of income and expenditure pertaining to prior period are accounted through "Prior Period Adjustment Account" and extra ordinary item.

s. Excise Duty

- a) Excise Duty on manufactured excisable goods has been accounted on the basis of both payment made in respect of goods cleared as also provision made for goods lying in godown and accordingly liability of excise duty is provided Rs.58821/- (P.Y. Rs.199697/-) as certified by the Management.
- Excise duty on sales amounting to Rs. 348385.00 (P.Y. 382455.00) has been reduced from sales in profit & loss account and excise duty on stock amounting Rs. 29300.00 (P.Y. 58821.00) has been considered in the financial statement.

u. Contingencies and Events occurring after the Balance Sheet date.

Accounting for contingencies (gains and losses) arising out of contractual obligations, are made only on the basis of mutual acceptances. Events occurring after the date of the Balance Sheet are considered up to the date of approval of the accounts by the Board, where material.

v. Impairment of Assets

An asset is treated as impaired when the carrying cost of assets exceeds its recoverable value. An impairment loss is charged to the Profit & Loss Account in the year in which an asset is identified as impaired. The impairment loss recognized in prior accounting period is reversed, if there has been a charge in the estimate of recoverable amount. By virtue of this Company has carried out comprehensive exercise. To Assess the impairment loss of assets based on such exercise. There is no impairment of assets accordingly no adjustment in respect of loss or impairment of assets is required to be made in the accounts.

B NOTES TO ACCOUNT

- 1. As on 31st March 2009, No supplier has intimated the company about its status as Micro or Small Enterprises or its registration with the appropriate authority under the Micro, Small and Medium enterprises development act 2006. However the total outstanding dues to Micro, Small and Medium enterprises separately given in note no 26 of notes to accounts.
- 2. The Company has filed its return of the income upto Assessment Year 2008-2009 and the Income Tax Assessment of the Company have been completed upto Assessment Year 2007-2008.
- 3. Travelling, Conveyance and Sales Promotion Expenses also included expenditure incurred by the Directors of the Company for the purpose of business of the Company.

4.	Co	<u>ntin</u>	gent Liability not provided	Current Year 2008-2009	Previous Year 2007- 2008
	1.		nk Guarantee in favour of the state of the s	1787000.00	Nil
	2.		im against the Company not nowledged as debts.		
		a.	Commercial Tax Authority (against Entry Tax)	82865.00	82865.00
		b.	Central Excise Authority	327190.00	Nil
		c.	Show Cause notice issued by The central excise department against Liability of excise duty on IV fluid. But same is pending For order (A/c year 2001-02 to 2007-08)	8473559.00	Nil

- No provision has been made in respect of certain overdue sundry debtors amounting to Rs. 2298654.60 (P.Y. Rs. 2475648.00) as there is reasonable certainty of recovering the entire due by virtue of continuing follow up with the concerned parties.
- 6. The company has not given any loan or advance in the nature of loan to its subsidiaries associates or firms/

******			the second s	
		the second s		
-	16TH ANNUAL REPORT		DESCRIPTION DESCRIPTION	C LIVATED
-	I IOIN ANNOAL KEPUKI		BERYL DRUG	
_				
-				

company in which directors are interested. However, there are no loan or advances in the name of loan where is

- a) No repayment schedule or repayment schedule beyond seven years or
- b) No interest or interest is below the rate specified in Section 372A of the Companies Act, 1956.
- 7. Working capital facilities are secured by hypothecation of stock of raw material, packing material and finished goods, stores and spares not relating to plant and machinery (consumable stores & spares) bills, receivables and book debts and all other movable both present and future. These are further secured by personally guaranteed by the Managing Director and Whole Time Director of the Company.
- 8. Installment of Hire purchase term Loan From ICICI Bank falling due within one year are Rs. 162812.00 (R.Y. Rs. 3080640.00)

9.	Payment to Auditors	Current Year	Previous Year
		2008-2009	2007-2008
	1. Audit Fees	20,000.00	20,000.00
	2. Tax Audit Fees	10,000.00	10,000.00
	3. Service Tax	3090.00	Nil
r	Total	33090.00	30000.00
		======	
9.	Managerial Remuneration		
		Current Year	Previous Year
		31.03.2009	31.03.2008
	a) Salary to, Managing Director /	6,00,000.00	6,00,000.00

Whole time Director

- b) The company has been advised that, the computation of Net Profit for the purpose of Managerial Remuneration under section 349 of the Companies Act, 1956 need not to be enumerated since no commission by way of percentage of profit is payable for the year to any of the director.
- 11. Sitting fee payable to Directors have been waived by each one of them.
- 12. Loans & Advances including Rs.5628423/- (P.Y. Rs. 5902931.00) over due from other parties on account of advance against capital assets. Hence it is required to be strictly reviewed by the Management. However the Management is confident that the parties are discharging their contractual obligations and is hopeful of acquiring the goods or its settlement through full recovery thereof in due course.
- 13. The Company has not availed any Cenvat benefit on capital goods purchased during the year as informed by management.
- 14. All balances of debtors, creditors and advances are subject to analysis and confirmation by the parties. Because letter of confirmation of balance to parties have not been issued. The Management does not expect any material difference affecting the current year financial statement.
- 15. Corresponding figures of the previous year have been regrouped re-casted and re-arranged to make them comparable with current year's figures wherever necessary.
- 16. In the opinion of the Board of Directors the current assets, loans and advances including deposits have value on realization in the ordinary courses of business at least equal to the amount at which they are stated in the

Balance Sheet and provision for all known liabilities is adequate and not in excess of the amount reasonably necessary.

- 17. Provision for Income Tax has been made Rs. 207541.14 (P.Y. Rs.637310.00) in during the year in the account after considering provision of the Income Tax Act.
- 18 The Company availed Cenvat benefit on purchase of material and capital goods and netted from the cost of these goods/material. Cenvat is adjusted against excise duty to the extent utilized against clearance of the material.
- 19 All bank balances are subject to reconciliation with bank.
- 20 Commission on sales paid to selling agent is Rs. 1297786.00 (1292419.00) in during the year.
- 21 The Company has not appointed Whole Time Company Secretary as per requirement of Sec. 383A of the Companies Act, 1956 till date but management informed to us that they are in process to appoint Full Time Company Secretary and have take suitable effects for the same.
- 22 Other income includes Rs.48,000.00 (P.Y. Rs.48,000.00) as rent received from Beryl Securities Ltd., a Company under the same Management.
- 23 Provision for Wealth Tax has not been made because no liability comes on the Company as per the expert opinion obtained by the Management.
- 24 Additional information as far as applicable pursuant to the provisions of Paragraph 3, 4C, 4D of part II of the Schedule VI of the Companies Act, 1956 has been furnished as per Annexure I.
- 25 Balance Sheet abstract and the company's general business profit in pursuant to Part IV of Schedule VI to the Companies Act, 1956 has been furnished as per Annexure II.
- 26 Information relating to supplier under the provision of MICRO Small and medium enterprise development act, 2006.

Pa	rticulars	2008-09	2007-08
1.	The Amount due there on remaining Unpaid to any	Nil	Nil
	supplier as at the end of the year principle Interest		
2.	Payment made beyond the appointment Day and interest	Nil	Nil
	Day and interest during the year.		
3.	The amount of Interest due and payable for the period of	Nil	Nil
	for the period of delay in making payment but with out	2 ⁴⁶	
	adding but with out adding the interest specified in act.		
4.	The amount of Interest accrued and remaining unpaid	Nil	Nil
	remaining unpaid at the end of the year.		
5.	The amount of further Interest remaining due and payable	Nil	Nil
	in the due and payable in the succeeding year dntil the date	e	
	· · · · · · · · · · · · · · · · · · ·		

such interest is actually paid.

27. Disclosure in respect of related parties as per Accounting Standard 18 (AS-18) issued by the Institute of Chartered Accountants of India with whom transactions have been taken place during the year are given below.

16TH ANNU	AL REPORT			Ber			
Name of party	Relationship	<u>Nature of</u> Transation	<u>Volume of</u> Transation	<u>Volume of</u> Trans.	Balance	(Dr./Cr.)	
		· · · · · · · · · · · · · · · · · · ·	31.03.2009	31.03.2008	<u>31.03.2009</u>	<u>31.03.2008</u>	
1. Beryl Securite: Ltd.	s Common Control Co.		48000.00 (Cr.)	48000.00 (Cr.)	N/A	 N/A	``
	Investment in shares (Op.Bal.)	6784000 (Dr)		6784000.00 (DR.)	6784000.00 (DR.)	
2. Sanjay Sethi	Managing Director	Remuneration	300000.00 (Dr)	300000.00(Dr)	300000 (Dr)	N.A	
3. Sudhir Sethi	Executive Director	Remuneration	300000.00 (Dr)	300000.00	300000(Dr)	N.A	
4. Sanjay Sethi	Managing Director	Advance against traveling	300000.00 (Dr)	300000.00 (Dr)	Nil	131580.00 (DR.)	
5. Sudhir Sethi	Executive Director	do	300000.00 (Dr)	300000.00 (Dr)	Nil	64580.00 (DR.)	
Particulars given	above have b	een identified on	the basis of infor	mation available w	ith the Compa	ny.	

28 In accordance with the Accounting Standard-20 (AS-20) "Earning per Share" issued by the Institute of Chartered Accountants of India earning per share is calculated as follows:-

Pa	articulars	<u>31.03.2009</u>	31.03.2008
i)	Net Profit (after tax) available to shareholders	151997.59	15051.61
ii)	Weighted average No. of issued	5131000.00	5131000.00
	shares during the year		
iii)	Face Value of share	Rs.10/-	Rs.10.00
iv)	EPS (i) / (ii) (basic and diluted)	0.003	0.003
-	• · · · · · · · · ·		

29. The Company has substantial unabsorbed depreciation and carried forward losses as per Income Tax Act resulting in net deferred tax assets which are recognized in the Profit & Loss Account as a matter of prudence and in accordance with AS-22 issued by the ICAI. The major components of deferred tax assets / liabilities arising on account of timing difference are as follows.

Particulars	Deferred Tax	Current year	Deferred Tax
	Assets as on	Deferred tax (Assets)	Balance of Assets as on
	01.04.08	31.03.09	31.03.09
**	*		
Difference in books /		•	
Tax depreciation	902960.10	120752.62	1023712.72

- 30. Provision of Accounting Standard (AS-23) "Accounting of Investment in the Associate/corporate company is not considered as the Relevant Investment is not material.
- 31. The Company has not given any advance(s) in the nature of loan to any party as defined in clause 32 of the listing agreement. As per the company policy interest free loan given to employees are not considered under this clause. Loan and Advance in the nature of loans to associates/employees (disclosure pursuant to Clause 32 of the listing agreement.)

Name	Rate of Interest	Amt. outstanding			
		As on 31.03.09	Max. O/s during theyear		
	·····				
Beryl Securities Ltd.	N.A.	NIL	NIL		
Employees (as per the general policy of the Company)	N.A.	NIL	NIL		

-			and the second se		
-					
	16TH ANNUAL REPORT			IS LIMITED 🛱	-
	TOTIL AUTOAL VELOKT				

- 32 Entry tax liability has been provided as per Entry Tax Return filed However additional liability if any arising on assessment shall be provided for on completion of assessment.
- 33 Company has made the provision Rs.42082.86 on account of Fringe Benefit Tax as per u/s 115 WB of the Act for the year.

NOTE - Being the Pharmaceuticals co, rate has taken @5% on Conveyance & Traveling Exp.

34. Disclosure in respect of provision pursuant to Accounting Standard

Particular	Opening Balance 1-04-08	Provided during the year	Utilized during the year	Reversed during the year	Closing Balance 31.03.09
Provision for doubtful. Debts Advance	Nil	Nil	Nil	Nil	Nil
Provision for Income Tax	637310.00	207541.14	491131.00	887564.00	353720.14
Provision for Fringe Benefit Tax	103991.00	42082.86	49237.00	54754.00	96836.86
Proposed dividend on Equity Share	Nil	N.A	N.A	N.A	N.A

Signed to Schedule "01" to "22"

In terms of our report of even date attached,

For SUBHASH CHAND JAIN ANURAG & ASSOCIATES **Chartered Accountants**

S.C. JAIN (PARTNER)

(DIRECTOR)

FOR AND ON BEHALF OF THE BOARD

M.N. 72062

Place : Indore Date : 18th August, 2009

(MANAGING DIRECTOR)

Place : Indore Date : 18th August, 2009

ADDITIONAL INFORMATION AS PER PROVISION OF PARAGRAPH 3 4C 4D OF THE PART II OF SCHEDULE VI OF THE COMPANIES ACT, 1956 FOR THE YEAR ENDED 31ST MARCH 2009.

ANNEXURE - I

A) QUANTITATIVE INFORMATION IN RESPECT OF LICENSED & INSTALLED CAPACITY

S.N.	Item	Licensed (In La	Capacity akhs)	Installed Capacity (In Lakhs)		Installed Capacity (In Lakhs)	
		31.03.09	31.03.08	31.03.09	31.03.08	31.03.09	31.03.08
1	Small Volume Injection	120	120	120	120	7.14	20.08
2	Large Volume Injection	120	120	120	120	73.05	84.36

B) QUANTATIVE DETAIL OF MANUFACTURED GOODS THEIR SALES AND OPENING & CLOSING STOCK.

I. ANNUAL PRODUCTION (S.V.)

	PREVIOU	S YEAR	2007-200)8	· · · · · · · · · · · · · · · · · · ·	C	URRENT	YEAR 2	008-2009	
S. No.	NAME OF ITEM	SIZE	OPENING Stock	MANUF. QTY.	SALE QTY	CLOSING Stok	OPENING STOCK	MANUF. QTY.	SALE QTY.	CLOSING STOCK
A.	BRANDED									
1	Bericlox Inj.	500mg	18075.00	51500.00	41400.00	28175.00	28175.00	66325.00	58500.00	36000.00
2	Bericlox Inj.	1000m	9250.00	19475.00	15200.00	13525.00	13525.00	0.00	9250.00	4275.00
3	B-Toxime Inj.	1000mg	212.00	0.00	0.00	212.00	212.00	0.00	0.00	212.00
4	Bkacin Inj.	500mg	18000.00	225.00	16000.00	2225.00	2225.00	0.00	0.00	2225.00
5	Bmycetin Inj.	20ml	24.00	8076.00	8016.00	84.00	84.00	10452.00	2388.00	8148.00
6	Beri-Cef. Inj.	1000mg	10354.00	0.00	8640.00	1714.00	1714.00	8986.00	10700.00	0.00
7	Bk acin Inj.	100mg	5625.00	0.00	4000.00	1625.00	1625.00	0.00	0.00	1625.00
8	F. Neuron Inj.	30mi	264.00	7116.00	7380.00	0.00	0.00	0.00	0.00	0.00
9	P-Mol Inj.	30ml	19850.00	16525.00	32800.00	3575.00	3575.00	21900.00	24275.00	1200.00
	TOTAL (A)		81654.00	102917.00	133436.00	51135.00	51135.00	107663.00	105113.00	53685.00
B.	GENERIC									
1	Ampicillin Inj. I.P.	500mg	21960.00	365340.00	384900.00	2400.00	2400.00	881750.00	883750.00	400.00
2	Ampicillin Inj. I.P.	1000mg	15700.00	10025.00	16375.00	9350.00	9350.00	0.00	6825.00	2525.00
3	Analgin Inj. M.F.I	30ml	11475.00	0.00	8100.00	3375.00	3375.00	0.00	3175.00	200.00
4	Amikacin Inj. I.P.	100mg	2250.00	8875.00	11125.00	0.00	0.00	5475.00	5475.00	0.00
5	Cyamocobalamine Inj.	20ml	9900.00	16628.00	26508.00	20.00	20.00	29620.00	23850.00	5790.00
6	Chloroquin Phos. Inj.	30ml	6550.00	11800.00	9590.00	8760.00	8760.00	0.00	3900.00	4860.00
7	Diclofenac Sod. Inj.	30ml	600.00	63550.00	44950.00	19200.00 ·	19200.00	46250.00	50100.00	15350.00
8	Dexamethasone Sod. Inj.	2mí	4775.00	20700.00	20000.00	5475.00	5475.00	0.00	0.00	5475.00
9	Dexamethasone Sod. Inj.	10ml	1030.00	0.00	1000.00	30.00	30.00	0.00	0.00	30.00
10	Dexamethasone Sod. Inj.	30ml	6025.00	26325.00	27550.00	4800.00	4800.00	7200.00	12000.00	0.00
11	Dicyclomine HCI Inj.	30ml	7475.00	0.00	7475.00	0.00	0.00	0.00	0.00	0.00
12	Gentamicin Inj. I.P.	2ml	8825.00	0.00	2300.00	6525.00	6525.00	0.00	0.00	6525.00
13	Gentamicin Inj. I.P.	10ml	6000.00	0.00	0.00	6000.00	6000.00	0.00	0.00	6000.00
14	Gentamicin Inj. I.P.	30ml	984.00	30091.00	26300.00	4775.00	4775.00	11600.00	16200.00	175.00

3 Ξ

•

	PREVIOU	IS YEAR	2007-200)8		C	URRENT	YEAR 2	008-2009	
S. No.	NAME OF ITEM	SIZ	E OPENING Stock	MANUF. QTY.	SALE QTY.	CLOSING Stok	OPENING STOCK	MANUF. QTY.	SALE QTY.	CLOSING Stok
15	Metaclopramde Inj. I.P.	30ml	5925.00	0.00	5925.00	0.00	0.00	0.00	0.00	0.00
16	Cyanocobalamine Inj.	30ml	3900.00	0.00	3900.00	0.00	0.00	0.00	0.00	0.00
17	Chlorpheniramine Inj.	30ml	3375.00	0.00	3375.00	0.00	0.00	0.00	0.00	0.00
18	Oxytetracyline	30ml	6800.00	. 0.00	6800.00	0.00	0.00	12050.00	10355.00	1695.00
19	Oxytetracyline Vet	30ml	650.00	36125.00	36700.00	75.00	75.00	65450.00	59775.00	5750.00
20	Oxytetracyline Vet	100mi	0.00	0.00	0.00	0.00	0.00	4064.00	4064.00	0.00
21	Cloxacillin Inj	500mg	12750.00	0.00	12750.00	0.00	0.00	0.00	0.00	0.00
22	Glycin Irrigation Inj.	3000ml	108.00	12455.00	11556.00	1007.00	1007.00	9271.00	10238.00	40.00
23	Amikacin Inj. I.P.	10ml	2250.00	8875.00	11125.00	0.00	0.00	0.00	0.00	0.00
	TOTAL (B)		139307.00	610789.00	678304.00	71792.00	71792.001	072730.00	1089707.00	54815.00
тот	AL (A) + (B)		220961.00	713706.00	811740.00	122927.00	122927.001	180393.00	1194820.00	108500.00

II ANNUAL PRODUCTION (L.V)

	PREVIOL	JS YEAR	2007-200)8		С	URRENT	YEAR 2	008-2009	
Io.	NAME OF ITEM	SIZE	OPENING STOCK	MANUF. QTY.	SALE QTY.	CLOSING Stock	OPENING Stock	MANUF. QTY.	SALE QTY.	CLOSING Stok
	BRANDED									
	Berilyte M.C GL	500ml	2677.00	69922.00	64920.00	7679.00	7679.00	64877.00	67884.00	4672.00
	Berizole Inj. PP	500ml	2680.00	320.00	2640.00	360.00	360.00	0.00	240.00	120.00
	Berizole GL	500ml	60.00	4721.00	3945.00	836.00	836.00	5127.00	4140.00	1823.00
	Berilyte-M Inj. PP	500ml	3158.00	129397.00	123062.00	9493.00	9493.00	81941.00	76002.00	15432.00
	Berilyte-P Inj. PP	500ml	5323.00	118454.00	104678.00	19099.00	19099.00	195068.00	196583.00	17584.00
	10%Berifructo Inj. GL	500ml	1175.00	20417.00	17040.00	4552.00	4552.00	17946.00	14227.00	8271.00
	Berilyte-G Inj.	500ml	1350.00	6447.00	6793.00	1004.00	1004.00	2719.00	1776.00	1947.00
	Berilyte-G Inj. GL	500ml	1750.00	4597.00	4018.00	2329.00	2329.00	2797.00	3619.00	1507.00
	Berilyte - P GL	500ml	4324.00	99527.00	92460.00	11391.00	11391.00	105160.00	112353.00	4198.00
0	Berilyte P GL	250ml	6.00	5910.00	5880.00	36.00	36.00	9147.00	6360.00	2823.00
1	Berilyte P GL	350ml	4581.00	0.00	4560.00	21.00	21.00	12880.00	5610.00	7291.00
2	Brerilyte M GL	1000ml	154.00	16268.00	15921.00	501.00	501.00	27149.00	27650.00	0.00
3	Berilyte E GL	500ml	609.00	4434.00	2265.00	2778.00	2778.00	2301.00	2274.00	2805.00
5	Glybin- D	500 ml	461.00	0.00	0.00	461.00	461.00	0.00	461.00	0.00
6	Beritine inj. GL	400 ml	4815.00	0.00	2805.00	2010.00	2010.00	0.00	510.00	1500.00
7	Beritine-M inj. PP	1000ml	0.00	0.00	0.00	0.00	0.00	1199.00	1140.00	59.00
	TOTAL (A)		33123.00	480414.00	450987.00	62550.00	62550.00	528311.00	520829.00	70032.00
	GEMERIC									
	R.L. Inj. I.P. P.P	500ml	12048.00	1184278.00	1141490.00	54836.00	54836.00	844235.00	793045.00	106026.00
	R.L. Inj. I.P. Gl	500ml	4121.00	243638.00	233576.00	14183.00	14183.00	290300.00	295616.00	8867.00
	Ringer Lactate Inj. PP	1000ml	0.00	23412.00	20388.00	3024.00	3024.00	54938.00	57810.00	152.00
	Ringer Lactate Inj. Gl	1000ml	4050.00	35376.00	39236.00	190.00	190.00	67172.00	66946.00	416.00
	Ringer Lactate Inj. Gl	1000)ml	Omi 4050.00	0ml 4050.00 35376.00	0ml 4050.00 35376.00 39236.00				

	16TH ANNUAL REF	E					BER		UGS LIM	
	PREVIOU	S YEAF	R 2007-200)8			CURRENT	YEAR 2	008-2009	
S. No.	NAME OF ITEM	SIZE	OPENING Stock	MANUF. QTY.	SALE QTY.				SALE QTY.	CLOSIN Stoc
5	5%Dextrose Inj. I.P. Gl	500ml	7400.00	314423.00	300223.00	21600.00		313161.00		17439.0
6	5%Dextrose Inj. I.P. PP	500ml	2508.00	1190431.00	1114660.00	78279.00	78279.00	1020149.00	956970.00	141458.0
7	5%Dextrose Inj. I.P.PP	1000ml	81.00	21474.00	14240.00	7315.00	7315.00	58207.00	25541.00	39981.0
B	5%Dextrose Inj. I.P. Gl	1000ml	499.00	27552.00	23292.00	4759.00	4759.00	31809.00	33840.00	2728.
9	10%Dextrose Inj. I.P. PP	500ml	2556.00	211052.00	179520.00	34088.00	34088.00	273497.00	276253.00	31332.
10	10%Dextrose Inj. I.P. GI	1000ml	432.00	7416.00	5850.00	1998.00	1998.00	3853.00	5292.00	559.
11	10%Dextrose Inj. I.P. P.P	1000ml	540.00	0.00	540.00	0.00	0.00	0.00	0.00	0.
12	25%Dextrose Inj. I.P.GI	100ml	2050.00	66672.00	54925.00	13797.00	13797.00	85220.00	89926.00	9091.
13	50%Dextrose Inj. I.P.GI	100ml	766.00	5011.00	3700.00	2077.00	2077.00	4430.00	6127.00	380.0
14	D.N.S. Inj. I.P. PP	500ml	20953.00	1093572.00	1044469.00	70056.00	70056.00	1120722.00	1049335.00	141443.0
15	D.N.S. Inj. I.P. GI	500ml	22442.00	345199.00	343059.00	24582.00	24582.00	367786.00	373593.00	18775.
16	D.N.S. Inj. I.P. PP	1000ml	4949.00	20120.00	21924.00	3145.00	3145.00	51053.00	51861.00	2337.0
17	D.N.S. Inj. I.P. GI	1000ml	2340.00	46572.00	47302.00	1610.00	1610.00	76548.00	77900.00	258.
18	ISO D.N.S Inj. IP GI	500ml	2340.00	5468.00	4380.00	3428.00	3428.00	2802.00	3465.00	2765.
19	ISO D.N.S Inj. IP GI	1000ml	1926.00	2787.00	4707.00	6.00	6.00	6998.00	5022.00	1982.
20	0.33% D.N.S. Inj. I.P. GI	500ml	4461.00	5460.00	6510.00	3411.00	3411.00	2785.00	4416.00	1780.
21	0.45% D.N.S. Inj. I.P. GI	500ml	14.00	14061.00	12720.00	1355.00	1355.00	18505.00	16985.00	2875.
22	20% Mannitol Inj. I.P. Gl	100ml	1450.00	128940.00	117600.00	12790.00	12790.00	187710.00	176498.00	24002.
23	20% Mannitol Inj. I.P. Gl	300ml	0.00	30881.00	24465.00	6416.00	0.00	0.00	0.00	0.
24	N.S. Inj. I.P. PP	500ml	18724.00	596978.00	537875.00	77827.00	77827.00	858758.00	292648.00	643937.
25	N.S. Inj. I.P. Gl	500ml	4169.00	105853.00	105330.00	4692.00	4692.00	139299.00	137115.00	6876.
26	N.S. Inj. I.P. PP	1000ml	4764.00	13206.00	16692.00	1278.00	1278.00	37346.00	35440.00	3184.0
27	N.S. Inj. I.P. Gl	1000ml	2011.00	11187.00	11853.00	1345.00	1345.00	21276.00	22605.00	16.
28	N.S. Inj. I.P. Gl	100ml	3327.00	204652.00	183736.00	24243.00	24243.00	372118.00	367588.00	28773.0
29	Metronidazole Inj. Gl	100mi	1350.00	319297.00	305850.00	14797.00	14797.00	272547.00	250716.00	36628.0
30	10%Dextrose Inj. I.P. Gl	500ml	3355.00	95357.00	93735.00	4977.00	4977.00	121410.00	115828.00	10559.0
31	5%Fructose Inj. Gl	500ml	56.00	20211.00	14430.00	5837.00	5837.00	8906.00	11957.00	2786.0
32	Ciprofloxacin Inj. Gl	100ml	3657.00	179785.00	159980.00	23462.00	23462.00	138739.00	148058.00	14143.0
33	Ciprofloxacin Inj. PP	100ml	1657.00	78116.00	70055.00	9718.00	9718.00	40035.00	46471.00	3282.0
34	25%Dextrose Inj. I.P. PP	500ml	3543.00	0.00	3528.00	15.00	15.00	11664.00	11487.00	192.0
35	Metronidazole PP	100ml	21212.00	159153.00	168875.00	11490.00	11490.00	169363.00	169798.00	11055.0
36	20% Mannitol GI.	350ml	146.00	0.00	0.00	146.00	6562.00	30000.00	32636.00	3926.0
37	NS Irri. Inj. PP	3000ml	1538.00	11100.00	6224.00	6414.00	6414.00	4462.00	10192.00	684.0
8	1.6% NS Inj. GL	500ml	1946.00	5514.00	2970.00	4490.00	4490.00	4518.00	4748.00	4260.
9	Interaperitoneal Dialysis G	L 1000ml	3177.00	0.00	1962.00	1215.00	1215.00	0.00	855.00	360.
40	5% Dextrose	500ml	0.00	7061.00	6600.00	461.00	461.00	0.00	360.00	101.(
1	0.22% D. N. S. Inj. I.P.G.	500ml	0.00	0.00	0.00	0.00	0.00	1828.00	1395.00	433.
2	N.S. Inj. I.P.	250ml	0.00	0.00	0.00	0.00	0.00	3810.00	2910.00	900.
	TOTAL (B)		172558.006		6448471.00	555352.00	554891.00	7112321.00	6342265.001	325307.
ОТ	AL (A) + (B)		205681.007							

BERYL DRUGS LIMITED

C) RAW MATERIAL AND COMPONENTS CONSUMED. (QUANTITY IN NUMBER OF UNITS) (A) RAW MATERIALS

	CURRENT	YEAR 2	008-2009			PREVIC	OUS YEAR	2007-2008	
S. No.	NAME OF ITEM	OPENING STOCK	PURCHASE	CONSUMED	CLOSING STOCK	OPENING Stock	PURCHASE	CONSUMED	CLOSING Stock
	01	.04.2008			31.03.2009	01.04.2007			31.03.2008
2	PROPLENE GLYCON	596.000	16950.000	0.000	17546.000	1794.000	645.000	1843.000	596.000
3	DICLOFENEC SODIUM	12.500	0.000	0.000	12.500	38.750	50.000	76.250	12.500
4	QXYTETRACYCLINE HCL	50.000	275.000	0.000	325.000	75.000	150.000	175.000	50.000
5	DEXAMETHASON SODIUN PHOSPATE	1.400	13.000	0.000	14.400	4.900	4.500	8.000	1.400
6	THIAMINE HCL B6UM	2.500	0.000	0.000	2.500	0.000	5.000	2.500	2.500
7	CHLOROBUTOL	0.000	0.000	0.000	0.000	15.000	0.000	15.000	0.000
8	CYANOCOBAL. B-12	0.000	400.000	0.000	400.000	0.354	0.200	0.554	0.000
9	PARACETOMOL	50.000	150.000	0.000	200.000	89.000	0.000	39.000	50.000
10	METACLOPROMIDE	6.000	0.000	0.000	6.000	6.850	0.000	0.850	6.000
11	CHLOROQUINE PHOS.	0.000	0.000	0.000	0.000	0.000	25.000	25.000	0.000
12	GENTAMICIN SULPHATE	21.250	65.000	0.000	86.250	26.250	15.000	20.000	21.250
13	CLOXACILLIN SOD.	0.000	40.000	0.000	40.000	40.000	0.000	40.000	0.000
14	DEXTROSE 2	20997.000	120500.000	140414.800	1082.200	15238.000	120000.000	114241.000	20997.000
15	POTTASIUM CHLORIDE	60.000	570.000	579.450	50.550	160.450	600.000	700.450	60.000
16	SODIUM CHLORIDE	237.000	18300.000	18053.125	483.875	1997.340	16050.000	17810.340	237.000
17	SODIUM ACETATE	113.000	400.000	494.875	18.125	182.090	700.000	769.090	113.000
18	METRONIDOZOLE	29.000	225.000	199.550	54.450	117.300	200.000	288.300	29.000
19	CHLORAMPHENICOL	0.000	25.000	0.000	25.000	0.000	0.000	0.000	0.000
20	MANNITOL	209.000	6300.000	6341.600	167.400	285.000	4750.000	4826.000	209.000
21	CIPROFLOXACINE	26.000	60.000	59.390	26.610	13.000	60.000	47.000	26.000
22	SUCROSE	0.000	500.000	0.000	500.000	48.000	0.000	48.000	0.000
24	CALCIUM CHLORIDE	6.000	220.000	202.460	23.540	16.910	120.000	130.910	6.000
25	LIDOCAINE	25.000	0.000	0.000	25.000	31.800	0.000	6.800	. 25.000
26	CHLORPHENIRAMINE	6.000	0.000	0.000	6.000	6.000	0.000	0.000	6.000
27	DIABASIC POTASSIUM SUL	23.000	50.000	57.800	15.200	51.825	60.000	88.825	23.000
29	DICYCLOMINE	12.500	0.000	0.000	12.500	5.400	10.000	2.900	12.500
30	AMPICILLIN SOD.	0.000	520.000	0.000	520.000	90.000	180.000	270.000	0.000
31	SOD. METABI	21.000	80.000	83.180	17.820	7.945	90.000	76.945	21.000
32	MAG.CHLORIDE	20.000	180.000	161.310	38.690	60.600	90.000	130.600	20.000
33	AMIKACINE SUL.	0.000	10.000	0.000	10.000	0.000	1000.000	1000.000	0.000
34	SODIUM LACTATE	134.000	4010.000	3810.270	333.730	204.240	4400.000	4470.240	134.000
35	MONO PROPYLENE	0.000	2365.000	0.000	2365.000	0.000	1720.000	1720.000	0.000
36	FRUCTOSE	0.000	275.000	0.000	275.000	10.000	400.000	410.000	0.000
37	AMMONIUM CHLORIDE	17.000	0.000	10.850	6.150	5.500	40.000	28.500	17.000
38	CITRIC ACID	20.000	100.000	0.000	120.000	73.980	100.000	153.980	20.000
39	TINADAZOLE	15.000	0.000	0.000	15.000	15.200	0.000	0.200	15.000
40	LIGNOCAINE	6.000	0.000	0.000	6.000	6.620	0.000	0.620	6.000
41	AMIKACIN	0.000	10.000	0.000	10.000	6.500	0.000	6.500	0.000
42	GLYCIN	59.000	450.000	. 341.900	167.100	327.300	0.000	268.300	59.000
43	MONOETHANOL AMIN	0.000	200.000	0.000	200.000	159.000	0.000	159.000	0.000

(B) PACKING MATERIALS

	CUR	RENT YEA	R 2008-200)9		PREVI	OUS YEAR	2007-2008	
S. No,	NAME OF ITEM	OPENING Stock	PURCHASE	CONSUMED	CLOSING Stock	OPENING STOCK	PURCHASE	CONSUMED	CLOSING STOCK
		01.04.2008			31.03.2009	01.04.2007			31.03.2008
1	VAILS 30 ML	188768.00	251924.00	173722.00	266970.00	131800.00	248500.00	191532.00	188768.00
2	VAILS 20 ML	20022.00	27000.00	42075.00	4947.00	36650.00	0.00	16628.00	20022.00
. 3	VAILS 10 ML	39000.00	20400.00	5475.00	53925.00	89000.00	0.00	50000.00	39000.00
4	VAILS 5 ML	213957.00	1195320.00	1005000.00	404277.00	321500.00	309522.00	417065.00	213957.00
5	VAILS 2 ML	109300.00	, . 0.00	0.00	109300.00	130000.00	0.00	20700.00	109300.00
6	SEAL 13/20 MM	364784.00	3590000.00	2459400.00	1495384.00	249000.00	600000.00	484216.00	364784.00
7	LABEL	5737000.00	12526504.00	13465004.00	4798500.00	4400000.00	7837000.00	6500000.00	5737000.00
8	INER	34000.00	70108.00	71508.00	32600.00	71000.00	13096.00	50096.00	34000.00
9	OUTER (CORR. BOX)	46050.00	339265.00	355599.00	29716.00	26774.00	3034278.00	3015002.00	46050.00
10	ALLUNINIUM SEAL32N	IM 378900.00	3145000.00	3170750.00	353150.00	128000.00	2332500.00	2081600.00	378900.00
11	HANGER 540ml	615.00	1225400.00	1220178.00	5837.00	, 44000.00	1287000.00	1330385.00	615.00
12	HANGER 1000ML	902232.00	241000.00	1131916.00	11316.00	32390.00	1017000.00	147158.00	902232.00
13	RUBBER 20MM	0.00	0.00	0.00	0.00	577000.00	559000.00	650000.00	486000.00
14	BOTTLE 1 LTR GL	1415.00	261370.00	254828.00	7957.00	2091.00	146482.00	147158.00	1415.00
15	BOTTLE 500 ML GL.	115965.00	1536432.00	1625610.00	26787.00	13982.00	1432368.00	1330385.00	115965.00
16	BOTTLE 100 ML GL	12586.00	990636.00	982382.00	20840.00	4810.00	969617.00	961841.00	12586.00
17	BOTTLE 375 ML	5869.00	52080.00	46259.00	11690.00	2250.00	34500.00	30881.00	5869.00
18	BOTTLE 3000 ML	5995.00	15798.00	21143.00	650.00	10100.00	19450.00	23555.00	5995.00
19	PLUG 32 MM	550000.00	2812000.00	3340550.00	21450.00	150000.00	2400000.00	2000000.00	550000.00
20	PP GRANULE	47843.00	124375.00	158143.00	14075.00	8850.00	190493.00	151500.00	47843.00
21	PLOYSTER FLIM	0.00	0,00.	0.00	0.00	18200.00	0.00	18200.00	0.00
22	BOTTLE 2 LTR	820.00	0.00	0.00	820.00	1620.00	0.00	1000.00	620.00
23	PPM	0.00	0.00	0.00	0.00	19850.00	0.00	19850.00	0.00
24	HANGER 250/375 ML	0.00	81000.00	56000.00	25000.00	0.00	0.00	0.00	0.00
25	PP BAG	0.00	8386.87	7296.87	1090.00	0.00	0.00	0.00	0.00

BERYL DRUGS LIMITED

D) VALUE OF IMPORTED AND INDIGENOUS RAW MATERIAL AND COMPONENTS CONSUMED.

S.N.	PARTICULARS	31.	03.2009	31.03.2008		
0.11		%	Amount	%	Amount	
1	Imported	N.A	Nil	N.A.	Nil	
2	Indigenous A) Material Consumed		100% 46535806.21	100%	41675266.00	
	B) Consumable Goods		1137109.00		9242805.00	

E) VALUE OF IMPORT OF CIF BASIS.

S.N.		. 31.03.2009	31.03.2008
1	Raw Materail & Component	Nil	Nil
2	Capital Goods	Nil	Nil
3	Spare Parts	Nil	Nil
4	Traded Item	Nil	Nil

BERYL DRUGS LIMITED

F) EXPENDITURE IN FOREIGN CURRENCY.

S.N.	PARTICULARS	31.03.2009	31.03.2008
1	Travel	Nil	Nil
2	OTHER	Nil	Nil
3	Spare Parts	Nil	Nil
4	Traded Item	Nil	Nil

Signed to Schedule "01" to "22" In terms of our report of even date attached

We Certify to the corrections of above

For SUBHASH CHAND JAIN ANURAG & ASSOCIATES Chartered Accountants

S.C. JAIN (PARTNER) M.N. 72062

FOR AND ON BEHALF OF THE BOARD

(MANAGING DIRECTOR)

(DIRECTOR)

Place : Indore Dated : 18th August , 2009 Place : Indore Dated : 18th August , 2009

	16TH ANNUAL REPORT			BERYL				
					ANNEXURE "II"			
	INFORMATION AS PER PART IV OF SEHEDULE VI OF THE COMPANIES ACT 1956 Balance Sheet Abstract and Company's General Business Profits							
I)	Registration Details Registration No. 10-7840 of 1993	State Code		Balance Sheet Date 31-03-2009				
ll)	Capital Raised During the Year Public Issue NIL	Right Issue		Bonus Issue	Private Placement			
111)	Position of Mobilisation and De Totai Liabilities Share Holder Fund 64846715.96	ployment of Fund Total Assets 64846715.96						
a)	Sources of Funds Paid-up Capital 50594000.00	Reserve & Surplus 4752219.52		Secured Loans 9304684.44	Unsecured Loans 195812.00			
b)	Application of Funds Net Fixed Assets 2628968.69	Investment 6784000.00		Net Current Assets 30742034.79				
	Miscellaneous Expenditure NIL	Accumulated Loss NIL						
IV)	Performance of the Company Turnover 69841029.80 Profit (+) Loss (-) After Tax	Total Expenditure 70241931.30 Earning Per Share in	n Rs.	Profit Before Tax 280868.97 Dividend Rate %	7			
ا (۷	151997.59 Genetic Names Three Principle	0.03 Products / Services	of the	NIL Company (As per Mo	」 netary Term)			
	Item Code No. (ITC Code) Product Description Signed to Schedule "01" to "22" In	terms of our report o	of even	29.36 MEDICAL INJECTA date attached	BLE			
For SUBHASH CHAND JAIN ANURAG & ASSOCIATES Chartered Accountants			FC	OR AND ON BEHALF	OF THE BOARD			
	S.C. JAIN (Partner)		(MA	NAGING DIRECTOR)	(DIRECTOR)			
M.N. 72062 Place : Indore Dated : 18th August, 2009				: Indore : 18th August, 2009				
		44						

16TH ANNUAL REPORT BERYL DRUGS LIMITED **CASH FLOW STATEMENT ANNEXED TO THE BALANCE SHEET** FOR THE YEAR ENDED 31ST MARCH, 2009 For the year ended For the year ended 31st March, 2009 31st March, 2008 (Rs. in lacs) (Rs. in lacs) A. Cash Flow from Operating Activities Net Profit(+)/Loss(-) before tax and prior 7.337 (2.86)period adjustment as per P&L A/c Adjustment for Depreciation 32.66 35.942 Other Income (Rent & Bank Interest) (0.65)- 7.791 Miscellaneous Expenses W/o Nil Nil Interest & Finance Charges 12.32 13.259 44.33 41.41 ----------------_____ ------Operating Profit before working Capital changes 47.19 48.747 Adjustment for : Loan & Advances 16.503 21.66 Trade and other Receivables (69.82)46.22 - 42.03 Inventories 14.97 Trade payables 17.92 - 42.256 (10.27)- 21.563 --------------------Cash Flow (before extra ordinary item) 36.92 27.184 Net Cash outflow from operating activities 1. Prior Period item adjustment 0.03 -3.563_____ -----Net Cash from operating activities (A) 36.95 23.621 B) Cash flow from Investing activities Purchase of Fixed Assets (Net) - 40.53 (33.88)1. Other Income (Rent received) 0.504 2. 0.65 --------Net Cash outflow in investing activities (B) (32.54)-40.026 C) Cash flow from Finance Activities Secured Loan 17.43 8.794 1. 2. Unsecured Loan (2.75)-1.789Call in Arrears 0.35 3 1.97 4 Interest and Financial charges (12.32)-13.26------------Net cash inflow from Financing Activities (C) 4.33 (6.255)Net inflow/outflow in cash & cash equivalents (A-B-C) 8.74 (22.31)Cash and Cash equivalents as on 01/04/2007 5.78 28.09 ------------Cash & Cash equivalent as on 31 March, 2009 14.52 5.78 ____ ====== NOTE : Figures in bracket represent cash out flow As per our report even date attached. FOR SUBHASH CHAND JAIN ANURAG & ASSOCIATES FOR AND ON BEHALF OF THE BOARD **Chartered Accountants**

S.C. JAIN (PARTNER) M.N. 72062

Place : Indore Dated : 18th August, 2009 (MANAGING DIRECTOR) (DIRECTOR)

Place : Indore Dated : 18th August, 2009

4!

16TH ANNUAL REPORT		
	t	

This page is Intentionally left blank

BERYL DRUGS LIMITED REGD. OFFICE :133, KANCHAN BAG, INDORE - 452 001

FORM OF PROXY

I/We	resident of
being member(s) of the above named Compa	any hereby appoint Mr./Mrsany hereby appoint Mr./Mrsas my/ our proxy to vote for me/ our behalf at the Sixteenth
Annual General Meeting of the Company to	be held at Kanchan Palace, Community Hall, Nipania, Ring Road, otember 30th, 2009 and at any adjournment thereof.

Signed this day of		
Registered Folio No.		
No. of Shares Held	Affix	

Affix Re. 2 Revenue Stamp

NOTE:

- 1. A member entitled to attend and vote at the meeting, shall be entitled to appoint proxy to vote instead of himself.
- 2. Proxy is not need to be member of the Company.
- 3. This form thus completed, should be deposited at the registered office of the Company situated at 133, Kanchan Bagh, Indore 452 001 not later than 48 hours before the appointed time of holding of Annual General Meeting.

-<TEAR HERE>-

BERYL DRUGS LIMITED

Regd. Office : 133, Kanchan Bag, Indore - 452 001


ATTENDANCE SLIP

PLEASE COMPLETE THIS ATTENDANCE SLIP AND HANDED OVER AT THE ENTRANCE OF THE MEETING HALL.

I hereby record my presence at the Sixteenth Annual General Meeting of the Company, to be held at Kanchan Palace, Community Hall, Nipania, Ring Road, Indore (M.P.) 10.00 a.m. on Wednesday, September 30th, 2009 and at any adjournment thereof.

SIGNATURE OF THE SHAREHOLDER OR PROXY PRESENT

BOOK-POST (PRINTED MATTER)



133, Kanchan Bag, INDORE - 452 001 (M.P.)

è